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ABSTRACT 
Hearing loss affects approximately 1-3 live births per 1,000. Infants admitted to 
the NICU are at greater risk of hearing loss than infants in the newborn nursery. Family 
history, as well as very low birth weight and exposure to certain therapies such as 
assisted ventilation, are also risk factors associated with hearing loss. Many states 
mandate newborn screening for hearing loss after birth due to evidence that early 
diagnosis and intervention improve communication skills and school performance, but 
following these infants over time can be challenging. 
This retrospective study describes temporal trends in primary screening outcomes 
including screening rates, loss to follow-up, and screen sensitivity and specificity. It also 
evaluated the likelihood of newborn hearing screening, loss to follow-up, false-positive 
and false-negative results, as well as hearing loss diagnosis among at-risk infants. Time-
to-diagnosis for infants with and without screening was also assessed. The study utilizes 
a database of births and follow-up encounters for infants born in a large Texas  
integrated health system between 1996 and 2007.  
Most newborn hearing screening program outcomes have improved since 
implementation in 1996. Outcomes differ by group, with black infants having higher 
probabilities of being lost to follow-up and receiving a false-positive result, but a lower 
probability of hearing loss than the overall study population. Infants diagnosed with 
persistent pulmonary hypertension had a higher probability of a false-negative result. 
Infants with craniofacial anomalies and neonatal infections have 5-7 times higher 
iii 
probability of hearing loss than those without the diagnoses. The overall incidence of 
hearing loss among the study population was 5%. Survival estimates demonstrate that 
infants identified through screening have a higher probability of early diagnosis. Infants 
with false-negative screens have the same probability of early diagnosis as infants with 
no screen. 
The study findings can inform both policy and practice. Newborn hearing 
screening leads to earlier diagnosis of infants with hearing loss, but improving targeted 
follow-up of high risk NICU infants may lead to earlier diagnosis of infants with delayed 
onset of hearing loss. Community-based providers can monitor high risk NICU infants 
after discharge for potential hearing loss.  
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CHAPTER I  
INTRODUCTION 
Hearing loss affects approximately 1-3 live births per 1,000.1 Early diagnosis of 
and intervention for hearing loss is critical since early intervention is linked to improved 
communication outcomes and school performance.2-7 There are two types of hearing 
loss, conductive and sensorineural. Conductive hearing loss is caused by problems in the 
middle or outer ear.8, 9 As an example, conductive hearing loss can be caused by a 
buildup of fluid within the middle ear, which is common in neonates. Conductive 
hearing loss can be reversible and may even resolve without treatment.9 Alternatively, 
sensorineural hearing loss is caused by damage to the nerve endings that detect sound in 
the ear and is typically permanent.8, 9 Either type of hearing loss can occur in one or both 
ears and may be congenital, syndromic, or nonsyndromic.9 Infants and children may also 
be affected by a mix of both conductive and sensorineural hearing loss.9 Hearing loss 
can also be progressive or have delayed onset.8  
Infants admitted to the NICU are at greater risk of hearing loss than infants in the 
newborn nursery.10 Family history, as well as very low birth weight and exposure to 
certain therapies such as assisted ventilation, are risk factors associated with hearing 
loss.10 The US Preventive Services Task Force (USPSTF), the Joint Committee on 
Hearing (JCIH), and the Secretary’s Discretionary Advisory Committee on Heritable 
Disorders in Newborns and Children (SDACHDNC) have all recommended universal 
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newborn hearing screening,1, 10, 11 due to the associated risks, the availability of 
screening technology, and efficacy of treatment options.1   
Texas mandated universal newborn hearing screening in 199912 and HB 411 
modified the newborn hearing screening program from an opt-in to an opt-out program 
in 2011.13 HB 411 also outlined the process for follow-up of infants with a positive 
screen in 2011.13  
In 2011, the Texas Early Hearing Detection and Intervention (TEHDI) program 
reported that 58.2% of newborns, infants, and children that needed follow-up care after 
newborn screening received such care.14 This leaves 40.8% of children that were lost to 
follow-up due to: 1) truly not receiving any follow-up services, or 2) receiving services 
that were not reported to the TEHDI program.  
This study evaluates hospital-based implementation of newborn hearing 
screening before and after the passage of HB 411. This study is a longitudinal, 
retrospective database analysis of health and development of infants admitted to the 
NICU after birth, a special population of children with unique needs and utilization 
patterns. Analyses are performed using a highly comprehensive database of birth 
admissions over the period 1988-2009, from a large single health care system in Texas, 
serving an ethnically and racially diverse rural and exurban population. This database 
contains key data from admission to discharge as well as linked diagnosis data from 
follow-up encounters through 2013. This database of over 50,000 infants, including 
more than 9,000 NICU admissions. Seventy-eight percent of infants admitted to this 
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NICU have associated follow-up encounters within the same health system available for 
analysis. 
The primary outcomes of interest in the study are overall screening rates, loss to 
follow-up rates, screen sensitivity (and related false-negative rate), screen specificity 
(and related false-positive rate), and time-to-diagnosis for infants with hearing loss, 
adjusted for infant characteristics and clinical factors postulated as predictors of the 
outcomes. The specific aims and related hypotheses for the study include: 
Specific Aim 1: Describe existing database systems established to monitor and 
evaluate treatment of and outcomes in premature and low birth weight infants.  
Research questions: What current large-scale databases exist to allow research and 
quality improvement in treatment of premature and low birth weight infants? How do 
these compare with a single center database? 
Specific Aim 2: Assess temporal trends in screening rates, loss to follow-up, and test 
sensitivity and specificity after implementation of newborn hearing screening, and 
evaluate the likelihood of newborn screening, loss to follow-up, a false-positive 
result, a false-negative result, and hearing loss adjusting for infant characteristics 
and clinical factors.  
Hypothesis 1: Changes in policy and clinical practice improve newborn screening rates, 
loss to follow-up, and test sensitivity and specificity. 
Hypothesis 2: The likelihood of receiving a newborn hearing screen, being lost to 
follow-up, receiving a false-positive screen result or false-negative screening results, and 
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receiving a diagnosis of hearing loss vary based on infant characteristics and clinical 
factors.  
Specific Aim 3: Evaluate time-to-diagnosis for infants that receive a positive screen 
result prior to hospital discharge, and identify correlates of earlier diagnosis.  
Hypothesis: Time-to-diagnosis is earlier in infants that receive a positive newborn 
screen, but still varies by group (e.g. race/ethnicity). 
 In Chapter II below, I summarize the existing literature related to infant and 
childhood hearing loss, universal newborn hearing screening recommendations and the 
program in Texas as well as the health system in which this study occurred, and the 
history of and challenges in studying outcomes for infants at high-risk of hearing loss 
and other developmental outcomes. Chapter III describes the methodology utilized to 
test the hypotheses described above. Chapters IV and V include the study results and a 






This chapter summarizes the existing literature and research on hearing loss in 
infants and children. It also describes early detection of hearing loss and the efforts of 
state newborn hearing programs, recommendations for early intervention and hearing 
loss diagnosis, and known challenges in the long-term study of infants at greater risk of 
hearing loss. 
Risk Factors Associated with Hearing Loss 
Risk for congenital, delayed onset, or progressive hearing loss in childhood may 
be increased by any of the following:10 (a) family history, (b) NICU admission greater 
than five days or any of the following treatments within the NICU, regardless of length 
of stay – ECMO, assisted ventilation, exposure to ototoxic medications or loop diuretics, 
and hyperbilirubinemia, (c) in utero infection, (d) craniofacial anomalies, (e) physical 
findings associated with syndromes known to include hearing loss, (f) presence of 
certain syndromes associated with hearing loss, (g) neurodegenerative disorders, (h) 
post-natal infections such as bacterial meningitis, (i) head trauma, and (j) chemotherapy. 
The relative risk of each of these factors varies by study, however. Several recent studies 
have focused on examining the incidence of these risk factors in children with hearing 
loss15-19. Among these studies there is an inconsistency in results, suggesting that further 
study is necessary to fully understanding the contribution of certain risk factors to 




Infant and Maternal Characteristics Affecting Hearing Loss 
Other infant and maternal characteristics may also influence an infant’s risk of 
hearing loss. Family history is a known risk factor for hearing loss.10 Up to half of all 
hearing loss is attributable to genetic factors causing syndromes associated with hearing 
loss or increasing susceptibility to environmental factors that may cause hearing loss.20 
Studies suggest that the prevalence of hearing loss in children under the age of 20 may 
be higher in Hispanic infants and those in lower income households, but studies 
measuring these differences vary in design and study population.21 Naarden and 
Decoufle found that low birth weight infants, specifically those born at less than 2,500 
grams had a higher prevalence of bilateral sensorineural hearing loss, and that rates of 
hearing impairment were consistently higher among low birth weight black children 
compared to low birth weight white children.22 Finally, NICU infants may be 
particularly susceptible to delayed-onset hearing loss.23 
NICU Interventions Affecting Hearing Loss 
There are many advances in neonatology that have improved outcomes for 
infants born premature and/or at low birthweight. These infants have complex medical 
conditions and comorbidities associated with prematurity, respiratory distress for 
example, that significantly increase risk for mortality and morbidity. Technological 
interventions used to treat these infants in the NICU, such as assisted ventilation and 
extracorporeal membrane oxygenation (ECMO) therapy, have led to decreased mortality 
among low birth weight infants, but significant morbidities including hearing loss 
persist. In fact, an increased incidence of hearing loss among infants admitted to the 
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NICU has been observed.24 The following sections summarize both assisted ventilation 
and ECMO therapy in an effort to demonstrate the effectiveness of new NICU 
interventions and their potential to increase the likelihood of hearing loss in infants 
admitted to the NICU. These examples were chosen  since they are used to treat 
respiratory distress, which affects up to 7% of newborns and has a high incidence in 
preterm infants.25 This current study focuses on implementation and outcomes of 
newborn hearing screening within a population of NICU infants and, therefore, a brief 
discussion of two associated risk factors is relevant. 
The potential causes of respiratory distress include underdevelopment of the 
lungs, surfactant deficiency, transient tachypnea, infections, meconium aspirations 
syndrome, respiratory distress syndrome (hyaline membrane disease), and birth 
asphyxia.25, 26 Among preterm infants, respiratory distress syndrome accounts for up to 
30% of respiratory distress and may represent the greatest risk for mortality.25 Treatment 
of respiratory distress varies depending on severity. Antenatal corticosteroids, surfactant 
administration, oxygenation, and, in severe cases, mechanical ventilation or ECMO are 
potential treatments.26 Both assisted ventilation and ECMO are treatments primarily 
utilized in the NICU, and each is a known risk factor for hearing loss. Each of these 
neonatal treatment advances and their importance to studies of newborn hearing loss are 
described below.  
Assisted Ventilation 
Despite significant improvements in morbidity and mortality after the 
introduction of surfactant and increased use of antenatal steroids, the need for respiratory 
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support remains high among preterm infants.27, 28 Assisted ventilation allows for the 
provision of respiratory support to infants who are unable to breathe well on their own. 
Assisted mechanical ventilation was first introduced in the 1960s and now includes a 
variety of mechanisms for ventilation, some more invasive (e.g. requiring intubation) 
than others.28 Mechanical ventilation does have risks, including lung injury, pneumonia, 
chronic lung disease (including bronchopulmonary dysplasia), and mortality.29, 30  
Limited population-based epidemiologic data exists on ventilation strategies and 
outcomes. However, the NICHD Neonatal Research Network has collected data on 
premature and low birth weight infants for over two decades and has been used for 
epidemiologic study. Among very low birth weight infants, the length of ventilation 
using intubation techniques has decreased over time as has the percent of infants with 
respiratory distress syndrome, although respiratory distress syndrome remains 
particularly high among extremely low birth weight infants (500-1000g).31  Over the 
same time, mortality before discharge has decreased (although this study does not link 
decreased mortality to respiratory treatment improvements specifically) but morbidities 
such as bronchopulmonary dysplasia have not changed.31 
Several studies have found possible associations between assisted ventilation and 
hearing loss in patients with congenital diaphragmatic hernia, although the incidence of 
hearing loss varied significantly by study.32-34 In a Dutch study of risk factors for hearing 
loss in NICU graduates born at less than 30 weeks gestational age or with a birthweight 
less than 1000g, the authors found a significant association between assisted ventilation 
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of at least five days and hearing loss.35 Similarly, a study from China found that NICU 
admission along with assisted ventilation was a risk factor for hearing loss.36  
Extracorporeal Membrane Oxygenation 
In extreme cases of neonatal respiratory distress, ECMO may be used as a 
mechanism for external life support. ECMO was first used successfully in 1976.37 
ECMO is used to bypass the heart and lung while maintaining respiratory function and 
blood oxygenation.38 Clinical indications for ECMO include congenital diaphragmatic 
hernia, heart malformations, meconium aspiration syndrome, severe pneumonia, severe 
air leak syndrome, and severe pulmonary hypertension.37, 38 ECMO is not indicated for 
very preterm or low birthweight infants. In most cases, infants with gestational age less 
than 34 weeks or birth weight less than 2000g are not candidates for ECMO, due to 
increased risk for and incidence of intracranial hemorrhage.37  
ECMO use has declined since 1990, especially among patients with respiratory 
distress syndrome and sepsis or pneumonia.37 Infants eligible for ECMO treatment are 
already at extreme risk for death given their underlying medical conditions, but 
additional risks associated with ECMO treatment include bleeding, due to the use of 
heparin, blood clot formation, intracranial hemorrhage, infection, and transfusion 
problems.38 In the long-term, infants treated with ECMO may experience 
neurodevelopmental disorders such as cerebral palsy.39 Despite these risks, 
approximately 77% of ECMO patients survive although this varies by condition for 
which ECMO was indicated.37 A 2008 systematic review of ECMO trials found that use 
of ECMO provides strong benefit for infants in terms of mortality and decreased 
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likelihood of severe morbidity.40 A cost-effectiveness study using data from the United 
Kingdom Collaborative ECMO Trial found that ECMO is cost-effective compared to 
conventional management.41  
Associations between ECMO, and prolonged ECMO treatment, and hearing loss 
also appear to be positive.42-44 Infants undergoing ECMO therapy demonstrate a greater 
risk of hearing loss, possibly associated with low levels of carbon dioxide in the blood 
prior to ECMO.39 There is some evidence that ECMO therapy, especially, can result in 
delayed onset of hearing loss.42-44 For example, one study found that approximately half 
of infants identified with sensorineural hearing loss after ECMO therapy has previously 
passed a hearing test.42 Due to the potential for delayed onset, the JCIH has 
recommended additional audiologist assessment for infant with these risk factors, ideally 
between 24 and 30 months of age.10  
Both neonatal technologies (assisted ventilation and ECMO) have an impact on 
early screening and, potentially, long-term outcomes related to hearing. Both 
technologies are used to save infant lives, thus leading to more infants living for a longer 
period of time. However, assisted ventilation and ECMO may also induce unfavorable 
long-term outcomes such as hearing loss. It is not clear whether or not treatment for 
respiratory distress or the underlying cause of respiratory distress (e.g. poor lung 
function which limits oxygen intake) actually lead to increased risk for hearing loss. 
Nonetheless, assisted ventilation and ECMO appear to be good indicators of risk for 
hearing loss, and there is enough evidence to warrant recommendations for universal 
 11 
 
screening with targeted follow-up assessments for infants undergoing either treatment in 
the NICU.1, 10  
Universal Screening Programs 
Early identification of and treatment for hearing loss is important for preventing 
and improving long-term problems with speech, language, and/or communication.2-7 
Treatments include interventions such as hearing aid placement and cochlear implants to 
provide amplification, as well as speech therapy. Early intervention using these 
treatments, or others as indicated, may also improve school performance.7, 45  
In response to the growing body of evidence demonstrating the importance of 
early intervention, newborn screening for hearing loss has become prevalent across the 
United States and internationally. The US Preventive Services Task Force (USPSTF), 
the Joint Committee on Infant Hearing (JCIH), and the Secretary’s Discretionary 
Advisory Committee on Heritable Disorders in Newborns and Children (SDACHDNC) 
have all recommended universal newborn hearing screening.1, 10, 11, 46 Most states, 
including Texas, have mandated universal newborn hearing screening or, if the state 
does not mandate screening, report high rates of screening for infants.  
Newborn screening involves both biochemical screening tests using a small 
amount of blood taken from a newborn after birth and tested by the state, and point-of-
care tests where technology is used at the bedside to screen for disorders such as hearing 
loss or critical congenital heart defects. In point-of-care screening, a technician, nurse, or 
other professional performs and interprets the screening result. There are two types of 
technologies typically used in universal newborn hearing screening programs, 
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otoacoustic emission testing (OAE) and auditory brainstem response testing (ABR). 
OAE testing relies on obtaining responses from the cochlea when sound is presented, 
while ABR is used to detect electrographic activity of sound as it moves along the 
auditory brainstem.9  
In newborn screening, legal mandates, clinical practice guidelines, and screening 
technologies influence program administration, including documentation of follow-up, 
and clinical practice. The following paragraphs summarize laws, clinical practice 
guidelines, and changing screening technologies that have or may influence early 
detection of hearing loss. 
Texas mandated universal screening in 1999 through House Bill 714, but the 
program did not require participation for hospitals with less than 1,000 births per year 
and required parents to opt-in to the screening with written consent.12 The bill required 
full implementation by April 1, 2001, required informed consent from the parents, and 
outlined no specific protocols for screening infants admitted to the NICU. The bill also 
required birthing facilities that performed newborn hearing screening to report the 
screening results to parents, the newborn’s physician, and the state health department.  
In 2011, the Texas Legislature amended Chapter 47 of the Health and Safety 
Code with House Bill 411 to change the program to no longer require informed consent, 
thus mandating hearing screening unless the parents choose not to participate. 
Additionally, HB 411 specifically outlined the follow-up protocols and the 
responsibilities of both the state and birthing facilities.13 The time frame of this study 
 13 
 
does not allow for measuring outcomes after implementation of HB 411; however, its 
relevance to the study is important in terms of continued investigation. 
The Joint Committee on Infant Hearing (JCIH), through its periodic statements, 
has recommended specific time frames within which infants should be screened, receive 
confirmatory testing, and receive intervention services.10 In addition, the JCIH has 
recommended separate screening protocols for infants admitted to the NICU versus 
infants admitted to the well-baby nursery.10 These practice guidelines are often 
disseminated through the peer-reviewed literature or professional meetings and may 
influence clinical practice before and after legal mandates require such practice. For 
example, the first JCIH statement on infant hearing screening was issued in 1995 
through the journal Pediatrics.47 The health system included in this study began newborn 
hearing screening, albeit not universally, in 1996, three years prior to HB 714 passing in 
Texas.  
Birthing centers also make relevant organizational decisions or policies that 
influence screening outcomes. The health system in which this study was performed 
made decisions regarding staff training and use of specific screening protocols. We 
know from physicians working within the health system at the time that somewhere 
around the year 2001, the organization recognized a pattern of high false-positive rates. 
As a result, they implemented a staff training program to improve not only the screening 
protocol used but also interpretation of results. 
Similarly, screening program outcomes may be impacted by the screening 
technology used to perform the hearing screen. In 2007, the JCIH recommended that 
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NICU infants be screened using ABR since their risk for hearing loss is greater than for 
non-NICU infants and the ABR testing methodology may be more sensitive to detecting 
the types of hearing loss for which NICU infants are at greatest risk.10 In the health 
system where this study took place, we know that the change to ABR screening in the 
NICU occurred prior to 2007, but the exact date is unknown.  
 This study will look specifically at the timing of these policy mandates and 
organizational changes to identify whether or not they influenced screening program 
outcomes including screening rates, false-positive rates, and false-negative rates. 
Unfortunately measurement of the program effects of changing screening technology is 
not possible since the available records do not differentiate between screening 
technologies. However, this contextual information may help to explain results.  In 
addition, the study looks at infant characteristics impacting the likelihood that an infant 
receives hearing screening, receives a false-positive result, or receives a false-negative 
result. Evaluation of screening program outcomes is important for quality improvement 
at the organizational-level and for informing future organizational and policy changes 
that impact hospital-based screening efforts.   Success of screening programs, however, 
should not be measured solely at the point of intervention but should look at outcomes of 
the program after the infant leaves the hospital, where they presumably receive follow-






Follow-up after a Positive Hearing Screen 
Beyond screening for hearing loss, state programs are tasked with providing or 
ensuring follow-up for infants that fail the hearing screen. These follow-up services 
include confirmatory testing and enrollment in early intervention programs. Historically, 
newborn hearing screening programs have a high number of infants “lost to follow-up,” 
ranging from approximately 35-45 percent from 2009 to 2012.48 Other reports indicated 
that the rate of loss to follow-up may be as high as 50% of all infants with a positive 
hearing screen, but this includes both infants that do not receive follow-up services and 
those that are lost to documentation, meaning that the receipt of follow-up services is not 
documented and therefor the status of those infants is unknown.49 In 2011, the Texas 
Early Hearing Detection and Intervention (TEHDI) program reported that 58.2% of 
newborns, infants, and children that needed follow-up care after newborn screening in 
Texas received such care.14 This results in 40.8% of children that were lost to follow-up. 
Lower rates of loss to follow-up lead to an increasing number of infants with hearing 
loss being identified50 and, presumably, receiving intervention services earlier. 
A 2008 technical report issued by the American Speech-Language-Hearing 
Association described a systematic review of existing literature on factors associated 
with loss to follow-up. The working group that prepared the report cited three potential 
areas in which issues can arise that impact loss to follow-up, including systems issues 
such as communication between providers, family issues such as socioeconomic status, 
and quality assurance issues such as electronic systems for reporting follow-up status.51 
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Most relevant to this study are the individual-level factors that may influence receipt of 
follow-up services.  
Several studies have examined the demographic and socioeconomic factors 
affecting whether infants receive follow-up services. Texas does not, at least publicly, 
report on loss to follow-up or enrollment in early intervention services by demographic 
or socioeconomic characteristics. However, a 2002 study from the Houston area 
compared newborn hearing screening and follow-up services at two centers, one serving 
a primarily indigent population and the other serving primarily private pay and Medicaid 
patients. The study found that infants born at the center serving mostly indigent patients 
were more likely to be lost to follow-up and less likely to be fitted for a hearing aid 
when one was indicated.52  
The Centers for Disease Control and Prevention (CDC) produces an annual 
report on state newborn hearing screening and early intervention programs. Using their 
2011 survey, demographic data indicate that the  percentage of infants evaluated after a 
failed newborn hearing screen increased with increasing maternal age and increasing 
maternal education.53 The percentage of infants evaluated after a failed newborn hearing 
screen varied by race/ethnicity, with infants of mothers of American Indian or Alaska 
Native and White Hispanic race/ethnicity having the lowest percentage.53 The 
percentage of infants enrolled in early intervention services increased with increasing 




A study of the Massachusetts newborn hearing screening follow-up program, 
which is statewide and multi-center, found that infants were more likely to be lost to 
follow-up if their mothers were non-white, received public insurance, smoked during 
pregnancy, or lived outside of the urban center (Boston).55 Even though this study found 
that living outside of the urban center was a risk factor for being lost to follow-up, they 
found that living in or near the urban center actually decreased the odds of receiving 
early intervention services.55Other studies have found that socioeconomic factors, such 
as public insurance, decrease the likelihood of follow-up,56-58 as well as infant race, 
infant birth weight, infant gender, and ventilator status.51 
The potential for delayed onset hearing loss means that some infants may not 
screen positive for hearing loss during the newborn period, thus increasing the likelihood 
of a false-negative at the first newborn screen. To be fair, this probably should not be 
counted as a false-negative since, presumably, the disease may not have developed prior 
to screening. Rather, this demonstrates the importance of targeted follow-up for infants 
with known risk factors. Although targeted follow-up is recommended by JCIH, the high 
lost to follow-up rates in state newborn screening program create a challenge for 
following infants through diagnosis and intervention. 
Future research on the etiology of newborn and childhood hearing loss is 
essential to improving screening, whether population-based or targeted, and long-term 
outcomes. Screening programs are currently focused on the newborn period and the 
potential for delayed onset may indicate a need to expand the scope of state newborn 
screening programs. Neonatal interventions such as ECMO are designed to decrease 
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mortality but may also be increasing morbidity, indicating a need for continued 
investigation into the pathophysiology by which clinical treatment causes hearing loss. 
This information may help researchers and providers identify clinical treatment 
modifications that reduce risk for hearing loss, and may assist screening programs in 
identifying appropriate time points for screening evaluations.   
Recommended Protocol for Newborn Hearing Screening and Follow-up 
The JCIH and the Centers for Disease Control and Prevention recommend a specific 
protocol for newborn hearing screening, and use this protocol to set national benchmarks 
for both quality improvement and Healthy People 2020. The protocol, titled “1-3-6,” is 
as follows:10, 59 
1. Infants will receive newborn hearing screening before 1 month of life. 
2. Infants that fail the newborn hearing screen will receive audiologic evaluation by 
3 months of age. 
3. Infants that have confirmed hearing loss should be fit for amplification (if desired 
by the family) within 1 month of diagnosis. 
4. Infants with confirmed hearing loss should be enrolled in early intervention 
services by 6 months of age. 
States, including Texas, manage early intervention programs to assist families in 
enrolling infants into services that help with the child’s speech, language, and social 
skills. This also includes connecting parents with other families affected by hearing loss. 
Additionally, the JCIH recommends that infants with risk factors associated with hearing 
loss, e.g. NICU admission, be monitored for hearing loss by their primary care 
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physician.10 NICU follow-up clinics, where available, may also perform these hearing 
assessments. 
 There are group differences in receipt of follow-up services. Previous studies 
have examined time-to-treatment performance within systems. Sininger, et. al. found 
that infants that received newborn hearing screening received diagnosis of hearing loss, 
were fitted for a hearing aid, and were enrolled in early intervention earlier than infants 
not receiving a newborn hearing screen.60 Spivak, Sokol, Auerback, & Gershkovich 
looked at referral for evaluation and fitting of hearing aids and found that less than one 
half of all infants were fit for a hearing aid on time (by 6 months of age).56 They also 
found associations between unilateral hearing loss and late diagnosis and late hearing aid 
fitting as well as loss to follow-up; and conductive hearing loss and Medicaid coverage 
and an infant being lost to follow-up.56 Knowledge of these differential effects of infant 
factors can inform future efforts to improve services delivery after newborn screening. 
Studying At-Risk Populations 
Infants admitted to the NICU and specifically infants with LBW are at increased 
risk for hearing loss and other short- and long-term morbidities. Studying of the impacts 
of prematurity and LBW is challenging due to the relatively small number of infants 
born with prematurity and/or LBW, and the difficulty in following those infants long-
term. 
Each year, prematurity and LBW impact a small but significant proportion of all 
live births in the United States. In the United States and internationally, improving 
outcomes for these infants remains a high priority. Healthy People 2020 includes 
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objectives to reduce LBW and premature births.61 These objectives include targets to 
reduce overall preterm births from 12.7% to 11.4% as well as specific objectives to 
reduce both very preterm and late preterm births by ten percent, and to reduce the 
number of LBW (8.2 to 7.8%), and very LBW  (VLBW) infants (1.5 to 1.4%).61 
 In the United States, overall infant mortality has declined from 100 per 1,000 live 
births in 1900 to 6.05 per 1,000 births in 201162 while remaining one of the highest 
infant mortality rates among industrialized countries.63 The development of medical and 
technological interventions has improved the survivability of premature and LBW 
infants. From 2000 to 2010 the infant mortality rate among preterm infants decreased 
from 37.88 deaths under age 1 per 1,000 live births to 34.22 per 1,000 live births, a 
decrease of almost 10 percent.64 For infants born under 32 weeks, the mortality rate 
decreased almost eight percent from 2000 to 2010, from 180.95 per 1,000 live births to 
165.57 per 1,000 live births.64 While overall infant mortality rates have decreased, they 
are still comparatively high and short- and long-term morbidities associated with 
prematurity and LBW have persisted.64, 65 There are a number of potential morbidities 
that affect nearly every organ system and include conditions such as poor 
neurodevelopmental outcomes, retinopathy of prematurity, severe intraventricular 
hemorrhage, hearing loss, bronchopulmonary dysplasia, respiratory distress syndrome, 
patent ductus arteriosus, necrotizing enterocolitis, and sepsis are associated with LBW 
and prematurity. These outcomes may be complicated by interventions to improve 
mortality such as ventilation65-73, transfusions and catheters - common interventions 
provided during a typical neonatal intensive care unit (NICU) hospitalization. 
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 Monitoring both short- and long-term outcomes of infants affected by preterm 
birth, LBW and VLBW is critical to advancing scientific and medical knowledge with 
respect to the development of more effective treatment guidelines, to improve quality of 
these treatments over time, and to minimize short- and long-term morbidities. Effective 
research can also inform integrated health care practices where surviving infants are 
treated through childhood and even into adulthood. However, studying infants affected 
by prematurity or LBW can be challenging due to small, single-center sample sizes, 
unknown quality of some administrative data, or limited availability of long-term 
follow-up data. 
To address these challenges, a number of large-scale databases were developed 
to allow structured study of premature and LBW infants, including but not limited to 
those admitted to the NICU.  In 1997, Wright and Papile summarized existing neonatal 
databases and their uses.74 Their review provided detailed descriptions of four neonatal 
databases: the Kaiser Permanente Neonatal Minimum Data Set (KPNMDS), the 
Vermont Oxford Network (VON), the Eunice Kennedy Shriver National Institute of 
Child Health and Human Development Neonatal Research Network (NICHD NRN), and 
the National Perinatal Information Center (NPIC).  Since 1997, there have been 
tremendous advances in neonatal care that have contributed to declines in infant 
mortality associated with prematurity or LBW, including the use of high-frequency 
ventilation and cooling caps. These clinical improvements are accompanied by an 
increasing number of studies aimed at evaluating neonatal intervention, understanding 
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the progression of disease, and investigating outcomes of those infants affected by 
prematurity or LBW.  
Existing Databases 
Of the four originally described by White and Papile, we are reviewing research 
progress using three, KPNMDS, NICHD NRN, and VON. The National Perinatal 
Information Center was not included in our review as their focus is on the perinatal 
period and not premature or LBW infants. The three databases have varying program 
goals, funding sources, strategies for data collection, and length of follow-up, but all 
focus on improving medical knowledge about and the quality of care provided to 
premature, LBW, and NICU admitted infants.  
The Kaiser Permanente Neonatal Minimum Data Set (KPNMDS) originated in 
1992 and is internally funded through the Kaiser Permanente (KP) system.75 The 
KPNMDS was developed to obtain reliable data about the NICU admission, and to 
support research and quality improvement efforts. The database includes both inborn and 
outborn admissions to at least six KP NICUs in Northern California, although the total 
number of NICUs participating in KPNMDS has increased since Wright and Papile 
described the database in 1997. The KPNMDS includes data on the full NICU 
admission, and some prospective studies using KPNMDS data extend follow-up for 
months or years after discharge from the NICU. The primary criterion for inclusion in 
the database is NICU admission, not a specific birth weight or gestational age. 
KPNMDS supports both retrospective and prospective studies.  
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The Vermont Oxford Network (VON) originated in 1989 and seeks to “improve 
the quality and safety of medical care for newborn infants and their families through a 
coordinated program of research, education, and quality improvement projects.”76 VON 
maintains two international databases, the Very Low Birth Weight Database and the 
Expanded Database, with a total of over two million infant cases.76 The Very Low Birth 
Weight Database includes inborn and outborn (if admitted within 28 days of birth) 
infants with birth weights below 1500 grams or gestational ages between 22 weeks 0 
days and 29 weeks 6 days.77 The Expanded Database includes all infants from the Very 
Low Birth Weight Database as well as infants born at more than 1500 grams and 
admitted to a NICU at a participating center, or “who die at any location in the center 
within 28 days of birth without first having gone home.”77 In 2012, VON reported 369 
centers reporting data on 153,093 infants into the Expanded Database, and 909 centers 
reporting data on 60,007 infants into the VLBW Database.77 VON members pay an 
annual membership fee and are eligible to use the data for studies, given strict adherence 
to data use guidelines set forth by VON leadership.78 In general, VON includes infant 
data through discharge, death, or one year of age although some prospective studies 
using VON have longer follow-up periods. VON supports both retrospective and 
prospective studies. NICUs may apply to participate in VON using a membership 
application and must pay a membership fee. 
The Eunice Kennedy Shriver National Institute of Child Health and Human 
Development (NICHD) Neonatal Research Network (NRN) began in 1986 and includes 
a registry to house data from multiple clinical trials funded through NICHD. NICHD 
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supports the NRN financially. Orginally, the NRN registry included data for inborn and 
outborn infants having a birth weight between 401 and 1500 grams.74 Since 2008, the 
database has included only inborn infants with a gestational age between 22 0/7 to 28 6/7 
weeks and/or a birth weight between 401 grams to 1000 grams.79 It also includes follow-
up data at 18-26 months, depending on the year of study and if the participating study 
site(s) assessed outcomes at such age as part of their research protocol.74, 79 As of August 
1, 2014, the NRN website listed 20 participating sites.80 NICHD NRN supports both 
retrospective and prospective studies, specifically clinical intervention and 
epidemiologic studies funded through NICHD. Participation in the NICHD NRN 
requires funding through NICHD, which is typically provided through a competitive 
grant process. 
All three databases use standardized forms and definitions for data submission by 
participating sites. In general, data use is open to participating sites contributing data to 
the database as long as database-specific requirements are met.  
These databases have continued to expand and become more widely used since 
they were first reviewed in 1997. In the systematic review described under Specific Aim 
1, I seek to provide a summary of how the databases are being used to advance scientific 
and clinical knowledge about the epidemiology of prematurity and LBW and the clinical 
treatment of those infants, in an effort to characterize the probability of using one of 
these databases to study screening for and diagnosis of newborn hearing loss. A further 
purpose is to offer clinical and health services researchers insight into how research on 
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preterm and LBW infants has evolved, and to offer strengths and opportunities for 






 This study focuses on three specific aims, as outlined in Chapter 1. The 
description of methodology employed for each is described below. 
Specific Aim 1 
Specific Aim 1: Describe existing database systems established to monitor and 
evaluate treatment of and outcomes in premature and low birth weight infants.  
Research questions: What current large-scale databases exist to allow research and 
quality improvement in treatment of premature and low birth weight infants? How do 
these compare with a single center database? 
Specific Aim 1 is motivated by the need to understand how existing, multi-center 
databases have been used to study the epidemiology of and outcomes for infants affected 
by LBW and prematurity. To achieve this, we employed a systematic review process to 
identify and characterize studies that have utilized data from one of three databases. The 
three databases of interest in the review are the Kaiser Permanente Neonatal Minimum 
Data Set (KPNMDS), the Vermont Oxford Network (VON), and the Eunice Kennedy 
Shriver National Institute of Child Health and Human Development Neonatal Research 
Network (NICHD NRN).   
We conducted a literature search using PubMed and Google Scholar of studies 
published over the time period January 1990 to August 15, 2014. Search terms included 
official names for each of the databases and their abbreviations, if applicable. For 
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example, the Kaiser Permanente Neonatal Minimum Data Set was searched for using the 
full name as well as “KP Neonatal Minimum Data Set” and “Kaiser Permanente 
Neonatal MDS.” None of the databases were searched for simultaneously, although 
several studies were returned during separate database searches.  
 Article titles and abstracts were reviewed for inclusion in our study. Initial 
inclusion criteria only required that the article include the name of one of the three 
databases and there was some evidence from the abstract that the study used or 
participated in the database network. Initial results were compared with publication lists 
maintained by the database managers. Both VON and NICHD NRN maintained such 
lists, which were last reviewed on August 15, 2014.  In both cases, additional studies 
were added into our review. 
 After title and abstract review, all articles were read to determine if the study 
used the database of interest as a data source for measuring the research question. The 
database could be used as a primary source of data or as a source of comparison or 
benchmark data. If either condition was true, the article was included in our study. 
Exclusion criteria included the following: descriptive articles summarizing database use 
or methodology, articles using similar but tangential databases such as the VON 
Encephalopathy Registry or Moderately Premature Infant Project database, articles 
referencing only definitions or tools (e.g. SNAP-II and SNAPPE-II) derived from or 
used within one of the databases, studies evaluating instrumentation or measurement 
technology, studies evaluating quality improvement processes implemented at study 
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sites participating in one of the database networks, review articles or meta-analyses, and 
non-English articles.  
 Studies were categorized as having either a retrospective or prospective study 
design. Retrospective studies were further sorted into categories based on use of the 
database as a primary data source or using it or its published findings as a comparison or 
benchmark for another study. A primary and secondary clinical focus area was also 
assigned to each individual study, in an effort to determine trends in research. To capture 
the overall clinical or outcome focus of the study, clinical focus area categories were 
applied first by the primary investigator, then reviewed by three other investigators for 
consistency. 
 The outcomes from Specific Aim 1 were reviewed when identifying and 
assessing the data source for the analyses in Specific Aims 2 and 3. The data elements of 
each database, as well as their stated length of follow-up on infants, were also 
considered. These factors were used to justify use of the single-center, longitudinal 
database used to analyze the hypotheses under Specific Aims 2 and 3.  
Specific Aim 2 
Specific Aim 2: Assess temporal trends in screening rates, loss to follow-up, and test 
sensitivity and specificity after implementation of newborn hearing screening, and 
evaluate the likelihood of newborn screening, loss to follow-up, a false-positive 
result, a false-negative result, and hearing loss adjusting for infant characteristics 
and clinical factors.  
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Hypothesis 1: Changes in policy and clinical practice improve newborn screening rates, 
loss to follow-up, and test sensitivity and specificity. 
Hypothesis 2: The likelihood of receiving a newborn hearing screen, being lost to 
follow-up, receiving a false-positive screen result or false-negative screening results, and 
receiving a diagnosis of hearing loss vary based on infant characteristics and clinical 
factors.  
The study under Specific Aim 2 utilizes a retrospective database of NICU and 
newborn nursery admissions over the period 1989 to 2009, from a large single health 
care center in Texas. This database contains key data from admission to discharge, 
including the date of the newborn hearing screen and the bilateral hearing screen results. 
For infants with at least one NICU admission, records are linked to the inpatient and 
ambulatory electronic medical record (EMR) in the same health system, allowing for 
detailed follow-up information regarding diagnoses received and morbidities these 
infants face as they mature through childhood. This database houses information on 
51,244 infants, including 9,219 infants with at least one NICU admission. Seventy-eight 
percent (78%) of all infants with a NICU admission have associated post-discharge 
follow-up encounters available for analysis. There is a mean of ten years of follow-up 
data on each infant for which follow-up is available. All patient and treatment factors as 
well as diagnoses were abstracted from this database.  
This study included inborn and outborn births between 1996 and 2007. Infants 
born prior to 1996 were excluded from analysis since newborn hearing screening did not 
begin in the center until 1996. Infants born after 2007 were excluded because the data 
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were incomplete for years following 2007. Further exclusion criteria were applied for 
each outcome of interest. To assess loss to follow-up, infants who were never admitted 
to the NICU, died prior to discharge, or received no hearing screen were excluded from 
analyses. Infants with no follow-up were further excluded from analyses of test 
sensitivity and specificity. Table 1 includes the exclusion criteria and sample sizes for 
each measure described below.  
 
Table 1. Model Exclusion Criteria and Sample Sizes 
Model Exclusion Criteria Final Sample Size 
Screening Rates 
Logistic Model for Receipt  
   of Newborn Hearing   
   Screen 
Births prior to 1996 and after  
   2007 (n=21,498) 
Remaining individuals with  
   incomplete data 
28,335 
Loss to follow-up Rates 
Logistic Model for Being  
   Lost to Follow-up 
Births prior to 1996 and after  
   2007 (n=21,498) 
Non-NICU admissions  
   (n=23,482) 
Deaths prior to discharge (n=73) 
Remaining individuals with  






Logistic Model for Receipt  
   of False-Negative Screen  
   Result 
Logistic Model for Receipt  
   of False-Positive Screen  
   Result 
Births prior to 1996 and after  
   2007 (n=21,498) 
Non-NICU admissions  
   (n=23,482) 
Deaths prior to discharge (n=73) 
Infants with no follow-up  
   (n=689) 
Remaining individuals with  
   incomplete data (n=767) 
5,002 
Logistic Model for Receipt  
   of Hearing Loss  
   Diagnosis 
Cox Proportional Hazards  
   Regression Model 
Births prior to 1996 and after  
   2007 (n=21,498) 
Non-NICU admissions  
   (n=23,482) 
Deaths prior to discharge (n=73) 
Infants with no follow-up  
   (n=689) 
Remaining individuals with  







Specific Aim 2 explores temporal trends in four outcomes of interest to newborn 
hearing screening programs: screening rates, loss to follow-up, test sensitivity, and test 
specificity. The formulas used to calculate each of the outcomes are described below. 
Annual newborn hearing screening rate =  # 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 ℎ𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖# 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑟𝑟𝑒𝑒𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑒𝑒𝑟𝑟 𝑜𝑜𝑜𝑜𝑟𝑟 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖  
Screening completion, or receipt of a hearing screen, was measured by 
identifying whether or not an infant has a screening result recorded during their birth 
admission. If a result is present, screening completion was coded as “yes.” The number 
of eligible infants was defined as the total number of infants admitted to either the NICU 
or newborn nursery. 
Annual loss to follow-up = # 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 𝑜𝑜𝑜𝑜𝑒𝑒𝑒𝑒𝑜𝑜𝑓𝑓−𝑢𝑢𝑢𝑢 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑟𝑟𝑖𝑖 𝑖𝑖𝑜𝑜𝑖𝑖𝑟𝑟𝑟𝑟 𝑖𝑖 𝑢𝑢𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟𝑟𝑟 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖# 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑓𝑓𝑖𝑖𝑖𝑖ℎ 𝑖𝑖 𝑢𝑢𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟𝑟𝑟 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖  
Receipt of follow-up services was defined as an infant having ever received 
follow-up within the health care system in which they were born. The screening result 
will be measured by analyzing the exiting hearing screen result from the infant’s record. 
In the database, screening result is coded as PP (pass in both ears), FP or PF (pass in one 
ear and fail in one ear), or FF (fail in both ears). These results were recoded into pass 
(PP) or fail (FP, PF, or FF). 
Sensitivity and specificity are typical measures of test or screening effectiveness. 
Sensitivity reflects the ability of a test to accurately identify individuals with the disease, 
and specificity indicates the ability of a test to accurately identify individuals without the 
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disease. These are closely linked to false-positive and false-negative rates.  These 
outcomes were calculated using the following formulas: 
Annual test sensitivity = # 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑓𝑓𝑖𝑖𝑖𝑖ℎ ℎ𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 𝑒𝑒𝑜𝑜𝑖𝑖𝑖𝑖 𝑓𝑓ℎ𝑜𝑜 ℎ𝑖𝑖𝑎𝑎 𝑖𝑖 𝑢𝑢𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟𝑟𝑟 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖
𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑒𝑒 # 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑎𝑎 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑎𝑎 𝑖𝑖𝑎𝑎𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑟𝑟𝑎𝑎 𝑓𝑓𝑖𝑖𝑖𝑖ℎ ℎ𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 𝑒𝑒𝑜𝑜𝑖𝑖𝑖𝑖  ) 
  False-negative rate = 1 – sensitivity 
Annual test specificity = # 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑓𝑓𝑖𝑖𝑖𝑖ℎ𝑜𝑜𝑢𝑢𝑖𝑖 ℎ𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 𝑒𝑒𝑜𝑜𝑖𝑖𝑖𝑖 𝑓𝑓ℎ𝑜𝑜 ℎ𝑖𝑖𝑎𝑎 𝑖𝑖 𝑖𝑖𝑟𝑟𝑟𝑟𝑖𝑖𝑖𝑖𝑖𝑖𝑟𝑟𝑟𝑟 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖
𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑒𝑒 # 𝑜𝑜𝑜𝑜 𝑖𝑖𝑖𝑖𝑜𝑜𝑖𝑖𝑖𝑖𝑖𝑖𝑖𝑖 𝑖𝑖𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑟𝑖𝑖𝑟𝑟𝑎𝑎 𝑖𝑖𝑖𝑖 𝑦𝑦𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑓𝑓𝑖𝑖𝑖𝑖ℎ𝑜𝑜𝑢𝑢𝑖𝑖 ℎ𝑟𝑟𝑖𝑖𝑟𝑟𝑖𝑖𝑖𝑖𝑟𝑟 𝑒𝑒𝑜𝑜𝑖𝑖𝑖𝑖  
   False-positive rate = 1 – specificity 
Confirmed hearing loss is defined as having a prevalent diagnosis as identified 
using ICD-9CM codes from the follow-up record. A total of 10 ICD-9CM codes were 
identified as primary codes for hearing loss.81 These ten ICD-9CM codes are listed Table 
2. Given the sample sizes in this study, hearing loss was coded as a binary variable if an 
individual was given any of these hearing loss diagnoses. Separate analyses were not 
performed for different types of hearing loss. 
 
Table 2. ICD-9CM Codes used to Identify Hearing Loss 
389.00 Conductive hearing loss, unspecified 
389.10 Sensorineural hearing loss, unspecified 
389.11 Sensorineural hearing loss, bilateral 
389.12 Neural hearing loss, bilateral 
389.14 Central hearing loss, bilateral 
389.15 Sensorineural hearing loss, unilateral 
389.16 Sensorineural hearing loss, asymmetrical 
389.18 Sensorineural hearing loss of combined types, bilateral 
389.2 Mixed conductive and sensorineural hearing loss 





Specific Aim 2 also includes analyses to assess the likelihood of receiving a 
newborn hearing screen, receiving of a positive screen result, being lost to follow-up, 
receipt of a false-positive result, receiving a false-negative result, and receiving of a 
hearing loss diagnosis, adjusting for infant characteristics. Both infant characteristics and 
co-occurring diagnoses are included in the analysis. Co-occurring diagnoses were 
identified using ICD-9CM codes. Table 3 summarizes the factors assessed. 
 





Length of Stay 
Apgar (1 minute and 5 minute) 
Treatment Factors associated with hearing loss or common in NICU 
Ventilation Status 
Oxygen Status 
Primary Diagnoses from the birth encounter associated with hearing loss or therapies 
associated with hearing loss (e.g. ECMO) 
Cytomegalovirus Dx (ICD-9CM: 771.1) 
Craniofacial Anomoly Dx (ICD-9CM: 756.0) 
Neonatal Infection Dx (ICD-9CM: 760.2, 771.82) 
Hyperbilirubinemia Dx (ICD-9CM: 774.6, 774.2) 
Sepsis Dx (identified through database notation, not diagnosis code) 
Respiratory Distress Dx (ICD-9CM: 769) 
Meconium Aspiration Dx (ICD-9CM: 770.12) 






Tests for temporal trends were performed to characterize the data and identify 
any year in which the outcomes were significantly different from the first year of 
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screening. Generalized linear models were used to test for trends in each of the rates 
from the first year of screening (1996) through 2007. All statistical analyses were 
performed using STATA 13.82 Results with p-values less than 0.05 were considered 
significant. The empirical models are as described below. 
Annual Screening Rates 
Screening rates were calculated for each year and the model includes the 
admitting unit (newborn nursery or NICU) as a covariate. Birth year is used as a trend 
variable to mark changes. Attempts were made to use an indicator variable for pre- or 
post-policy change but these were excluded due to collinearity. The model specification 
is below: 
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝛽𝛽2(𝑋𝑋2) +  𝜀𝜀  
Where: 
Y = Annual screening rate 
X1 = birth year 
X2 = admitting unit 
Annual Loss to Follow-up 
Rates of loss to follow-up were calculated for each year and only for infants 
admitted to the NICU.  Again, covariates indicating policy changes were excluded due to 
collinearity, so birth year itself is used as a trend variable to mark changes. This was the 
only covariate included in the model. The model is defined below. 





Y = Annual rate of loss to follow-up 
X1 = birth year 
Annual Test Sensitivity 
Sensitivity rates were calculated for each year and only for infants admitted to 
the NICU and with at least one follow-up encounter.  Covariates indicating policy 
changes were excluded due to collinearity, and birth year itself is used as a trend variable 
to mark changes. The model is as follows. 
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝜀𝜀  
Where: 
Y = Annual sensitivity rate 
X1 = birth year 
Annual Test Specificity 
Specificity rates were calculated for each year and only for infants admitted to 
the NICU and will at least one follow-up encounter.  Covariates indicating policy 
changes were excluded due to collinearity, and birth year itself is used as a trend variable 
to mark changes. The model specification are: 
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝜀𝜀  
Where: 
Y = Annual specificity rate 





Separate multivariate logistic regression models were used to assess the 
likelihood of an infant receiving a newborn hearing screen, being lost to follow-up, 
receipt of a false-positive result, receiving a false-negative result, and receiving of a 
hearing loss diagnosis, while adjusting for infant characteristics and birth year (as an 
indicator of policy/organizational change). These epidemiologic inquiries are useful for 
identify risk factors for the outcomes of interest. Robust standard errors were used to 
estimate variance of the maximum likelihood functions. 
Where significant differences were identified, marginal effects were calculated to 
identify the difference in probabilities. Marginal effects are historically used in 
economic analysis but can be useful for interpreting results in health services research 
and weighing decision options.83 Analyzing marginal effects allows researchers to 
determine the “incremental difference in outcomes between defined groups” (page 98).84 
Here, I use average marginal effects, which estimate the marginal effect based on the 
calculated average for each individual in the sample,84 to contextualize the differences in 
terms of probability of outcomes for groups within each significant model covariate. The 
models for each analysis are presented below. 
Receipt of Newborn Hearing Screen 
The outcome variable of interest in this model is receipt of a newborn hearing 
screen. This analysis was performed using infants admitted to both the newborn nursery 
and NICU, therefore the admitting unit is included as a covariate. The model also 
includes infant characteristics for adjustment. 
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𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝛽𝛽2(𝑋𝑋2) + 𝛽𝛽3(𝑋𝑋3) +   𝜀𝜀  
Where: 
Y = newborn hearing screen completion (1 = yes, 0 = no) 
X1 = birth year 
X2 = admitting unit 
X3 = vector of infant characteristics including gender, birthweight, race, Apgar scores, 
length of stay, oxygen status, ventilation status, and disorders reported as risk factors for 
hearing loss (see Table 3); in this model I also include an interaction for birth year and 
admitting unit 
Loss to Follow-up  
The outcome variable of interest in this model is lost to follow-up. This analysis was 
performed using infants admitted to only the NICU, as follow-up records are only 
available for the NICU population. While other studies have found that distance from 
urban centers was associated with receipt of follow-up services after hearing screening, 
the available location information (zip code) in our dataset was inconsistent and there 
were a large number of infants for which this information was missing. Therefore, 
distance was not included in our model. 
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝛽𝛽2(𝑋𝑋2) + 𝜀𝜀  
Where: 
Y = screen result (1 = lost, 0 = not lost) 
X1 = birth year 
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X3 = vector of infant characteristics including gender, birthweight, race, Apgar scores, 
length of stay, oxygen status, ventilation status, and disorders reported as risk factors for 
hearing loss (see Table 3). 
False-Positive Result 
The outcome variable of interest in this model is receipt of a false-positive result. 
This analysis was performed using infants admitted to only the NICU, as follow-up 
records are only available for the NICU population. 
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝛽𝛽2(𝑋𝑋2) + 𝜀𝜀  
Where: 
Y = screen result (1 = false-positive, 0 = true-positive) 
X1 = birth year 
X2 = vector of infant characteristics including gender, birthweight, race, Apgar scores, 
length of stay, oxygen status, ventilation status, and disorders reported as risk factors for 
hearing loss (see Table 3) 
False-Negative Result 
The outcome variable of interest in this model is receipt of a false-negative 
result. This analysis was performed using infants admitted to only the NICU, as follow-
up records are only available for the NICU population. 
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝛽𝛽2(𝑋𝑋2) + 𝜀𝜀  
Where: 
Y = screen result (1 = false-negative, 0 = true-negative) 
X1 = birth year 
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X2 = vector of infant characteristics including gender, birthweight, race, Apgar scores, 
length of stay, oxygen status, ventilation status, and disorders reported as risk factors for 
hearing loss (see Table 3) 
Confirmed Hearing Loss 
The outcome variable of interest in this model is receipt of a hearing loss 
diagnosis. This analysis was performed using infants admitted to only the NICU, as 
follow-up records are only available for the NICU population. Screen result and birth 
year were not included in the model since the neither is an associated cause of hearing 
loss.  
𝑌𝑌 = 𝛽𝛽0 + 𝛽𝛽1(𝑋𝑋1) +  𝛽𝛽2(𝑋𝑋2) +  𝜀𝜀  
Where: 
Y = hearing loss (1 = hearing loss diagnosis, 0 = no hearing loss diagnosis) 
X1 = birth year 
X = vector of infant characteristics including gender, birthweight, race, Apgar scores, 
length of stay, oxygen status, ventilation status, and disorders reported as risk factors for 
hearing loss  (see Table 3) 
Specific Aim 3 
Specific Aim 3: Evaluate time-to-diagnosis for infants that receive a positive screen 
result prior to hospital discharge, and identify correlates of earlier diagnosis.  
Hypothesis: Time-to-diagnosis is earlier in infants that receive a positive newborn 
screen, but still varies by group (e.g. race/ethnicity). 
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 Specific Aim 3 centers around understanding whether or not receipt of a positive 
hearing screen is associated with earlier diagnosis of hearing loss, and identifies infant 
factors and comorbidities associated with earlier diagnosis. The study group included in 
this analysis included all infants admitted to the NICU in the health care center and 
having at least one follow-up encounter after discharge from the NICU. Infants born 
prior to 1996 and after 2007 were excluded from the study due to incomplete birth or 
follow-up data. A total of 5,502 infants were eligible for inclusion in the study. There 
were 647 infants with incomplete records on at least one of the variables, resulting in 
4,855 infants included in the sample. 
 Infant characteristics of interest to the study include both demographic factors as 
well as those that have been shown to affect both hearing status and the likelihood of 
receiving follow-up services. Table 3 lists the infant characteristics included. Birth year 
is also included in the analysis as a categorical variable to identify trends in earlier 
diagnosis given policy and organizational changes. The presence or absence of 
diagnoses known to increase risk for hearing loss, either congenital or delayed-onset, 
were also included based on reports of the Joint Committee on Infant Hearing and other 
studies.10, 15-19, 42 Both ventilation status and oxygen status were also included as 
treatment factors in the model. 
Specific Aim 3 employs survival analysis with the Cox proportional-hazard 
regression technique.85 This method accounts for the variable lengths of follow-up 
available for each individual and allows for censoring, which describes the point at 
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which the individual leaves the study and assumes future diagnosis is possible even 
though it was not captured in the study.   
The time-to-event of interest in this study is the time between NICU discharge 
and hearing loss diagnosis. Discharge date was selected as the starting point for time 
measurement since the hearing screen is typically performed in the days prior to 
discharge and I assume that referral for confirmatory testing would be provided at that 
point. Diagnosis date was ascertained by identifying the first hearing loss diagnosis in 
the infant record and abstracting the associated date from the database. Individual 
records were coded as either having a documented hearing loss diagnosis or being 
censored after the date of their last follow-up encounter. Individual and treatment factors 
were included in the Cox Proportional Hazards model to identify correlates of early 
diagnosis. STATA software was used for analyses.82 Results with p-values less than 0.05 
were considered significant.  
The proportional hazards assumption is inherent to the Cox Proportional Hazard 
regression model and states that the hazard for any one individual is proportion to the 
hazard for any other individual, and that this proportionality is constant over time.85 The 
proportional hazards assumption was assessed by graphic modeling, specifically using 
log-log plots,85 and using statistical tests performed with the estat phtest command in 
STATA 13. Both assessments found that that the baseline hazards for the categories of 
screen result (no screen, screen negative, screen positive) were not proportional and the 
proportional hazards assumption for this predictor was not met. As a result, a stratified 
Cox Proportional Hazards model was used to estimate differences in diagnosis based on 
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infant and treatment factors, presumably similar to the results from the logistic model 
evaluating risk factors associated with a hearing loss diagnosis (see Specific Aim 2). The 
model was stratified by screen result and, therefore, hazard ratios are not available for 
this variable. However, through stratification, all results are adjusted for screen status. 
Independent survival curves were prepared for each significant covariate, as well as for 
screen result. Log-rank tests for equality of survival curves were conducted to see if 
there were statistically significant differences in the survival estimates for different 
groups. 
Median time-to-diagnosis and annual ranges, were also calculated for each year 
included in the study. These were plotted on a graph with a trend line to demonstrate the 
direction of changes over time.  
Limitations of Methodology 
 This methodology is limited by several factors. First, I use ICD-9CM codes as an 
indicator of disease. ICD-9CM codes can be unreliable due to the fact that they are 
applied for billing purposes and may not always be an accurate indicator of disease 
status.86 Full chart reviews were impractical in the study and, therefore, disease status 
could not be confirmed. Second, one of the well-known risk factors for hearing loss is 
family history, which could not be measured using these data. As a result, the models 
may include some level of misspecification due to a known but unmeasurable 
confounder. Finally, test of goodness of fit produced non-significant results for all 
models except in the logistic models for receipt of a newborn hearing screen and receipt 
of a false-positive result. The sample sizes included in the analyses for each model were 
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large, which may bias goodness of fit results. However, this may indicate that the models 
are somehow misspecified.  
  






 The results presented below are organized by specific aim. Sample sizes for each 
part of the study or individual model are noted in each section. A discussion of results 
and their implications for policy and practice are in Chapter V. 
Specific Aim 1 
A final total of 343 studies published between 1990 and 2014 were included in 
the review. Figure 1 summarizes the abstraction process and the final number of studies 
included across databases.  
 
 
Figure 1. Database Review, Study Abstraction Process 
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 The total number of publications using the databases has increased, from three in 
1991 to 41 in 2013 (the last full calendar year included in our review). Both prospective 
and retrospective studies have also increased, with retrospective studies comprising more 
of the total number of studies in most years. Around 2005, there was a slight decline in 
the number of studies published, but publications began to increase again after 2006. 
Figure 2 summarizes the year-by-year results.  
 
 
Figure 2. Annual Publications by Study Design 
 
Seventy-one percent (71%) of the studies used a retrospective study design and 
these studies tended to have an epidemiologic focus. Among retrospective studies, the 
database was sometimes used as a comparison group or benchmark for a single-center 
 46 
 
study. For example, Pietz, Achanti, Lilien, Stepka, and Mehta studied the incidence of 
necrotizing enterocolitis (NEC) in a single NICU over the course of twenty years. Their 
study looked specifically at the incidence of bowel perforation and NEC among a 
population of infants that were unlikely to have been treated with indomethacin, a 
nonsteroidal anti-inflammatory drug that can be used to treat very premature infants.  
Use of indomethacin in this particular NICU was discouraged and the authors emphasize 
the need to compare results to other centers that may use indomethacin more frequently. 
The study authors compared results from their NICU to overall results from VON, which 
likely included infants treated in NICUs employing more typical practice (for the time) 
of using indomethacin, and tested for differences in rates of NEC.87 Alternatively, 
retrospective studies also used the databases to study population health research 
questions. For example, Stoll, et. al. utilized the NICHD Neonatal Research Network 
database to retrospectively examine trends in morbidity and mortality among LBW 
infants.65 Smith, et. al., used the KPNMDS to study temporal trends in 
bronchopulmonary dysplasia rates over eight years.88 
Approximately 31% of studies utilized a prospective study design where the 
database was used as a sampling frame, or was used to house study data and answer a 
specific clinical research question. In their study of neurodevelopmental outcomes 
among extremely LBW infants (i.e., < 2000 g), Mercier, et. al., used the VON database 
as a sampling frame from which infants were identified for follow-up assessments.89 
Lorch, Srinivasan, and Escobar published a study on the epidemiology of apnea and 
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brachycardia in premature infants, which used the KPNMDS as a primary data source 
throughout the infants’ admission to the NICU.90  
 Studies focused on a variety of clinical conditions, interventions, and outcomes, 
with just over 70% of studies concentrating on ten categories (summarized in Table 4). 
The top ten areas of research focus were respiratory treatments/outcomes; 
neurodevelopmental, growth, or language outcomes; outcomes of  very LBW or 
extremely LBW; encephalopathy; neonatal infections; intestinal disease; sepsis; 
antenatal corticosteriod treatment; retinopathy of prematurity, and hyperbilirubinemia. 
The remaining 30% of studies focus on other specific conditions and interventions and 
account for a large amount of diversity in study focus areas. Approximately 10% of the 
studies were in a category alone, leaving 90% in categories with two or more studies.  
 
Table 4. Primary Clinical Areas of Focus for Studies Using Multicenter Neonatal 
Databases 
Primary Clinical Focus Area Count Percent 
(%) 
Citations 
Respiratory Treatments & Outcomes 67 19.53% 27, 70, 88, 91-153 
Neurodevelopmental, Growth, or 
Language Outcomes 
45 13.12% 
66, 69, 89, 154-195  
Outcomes of VLBW/ELBW 
39 11.37% 
65, 67, 68, 71, 72, 
196-229 
Encephalopathy 24 7.00% 230-253 
Neonatal Infections 18 5.25% 254-271 
Intestinal Disease  15 4.37% 87, 272-285 
Sepsis 14 4.08% 286-299 
Antenatal Corticosteriod Treatment 10 2.92% 300-309 
Retinopathy of Prematurity 8 2.33% 310-317 
Hyperbilirubinemia 8 2.33% 318-325 
Other 95 27.70% 90, 326-420  




Among those studies in the top ten categories, some were given a secondary 
clinical focus area to further describe the research. This occurred frequently in the 
broader categories looking at outcomes. For example, studies focusing on respiratory 
treatment and outcomes may have specific research questions related to use of surfactant 
or comparing ventilation strategies. Studies of neurodevelopmental outcomes tended to 
have secondary clinical foci on specific clinical conditions such as NEC, intraventricular 
hemorrhage, or hyperbilirubinemia. Other top categories, such as intestinal disease, had 
fewer secondary categories due, presumably, to the focus of the topic area. 
 Studies in each category also varied in terms of the range of time in which they 
were published. The earliest published studies focus on intestinal disease and overall 
outcomes of VLBW and ELBW infants, and these tend to continue through the duration 
of time included in our review. Alternatively, studies of heart defects and 
encephalopathy using one of the three databases were not published until after 2000. 





Figure 3. Study Trends, Top Ten Clinical Focus Areas, 1990-2014 
 
 Despite extensive datasets and the ability for diverse research aims, these 
databases are not ideal for all outcome studies of prematurity and low birth weight. In 
the context of this study of hearing loss among NICU infants, there are several specific 
concerns. First, there is limited evidence that hearing screening status is available for 
infants in any of the databases. Given my intent to assess implementation and outcomes 
of the screening policy, screening status is necessary. Second, these three databases do 
not report maintaining consistent long-term follow-up of infants. While some studies 
follow infants for extended periods of time, this is not a requirement for participation in 
the databases and, therefore, researchers cannot count on follow-up data on a large 
proportion of infants. Finally, and related to follow-up, hearing loss is a relatively rare 
disorder detected in newborns with an incidence rate of 1-3 per thousand in the general 
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population. To detect significant results in the NICU population, which is already small, 
I needed a large sample size. Although the three databases reviewed have a large number 
of included infants, there is likely a small number with hearing-related screen 
information or diagnoses after discharge from the hospital. Due to these concerns, I feel 
justified in using a longitudinal database from the single center where hearing screen 
results were documented routinely in the medical record and where there is a mean of 
ten years of diagnostic follow-up on infants receiving follow-up services within the 
center.  
Specific Aim 2 
 Here I present results for Specific Aim 2, which aims to look at temporal trends 
in newborn hearing screening, loss to follow-up, screen specificity and false-positive 
rate, and screen sensitivity and false-negative rate. In addition, I use logistic regression 
to predict the likelihood of an infant receiving a hearing screen, being lost to follow-up,  
receiving a false-positive and false-negative screen result, and receiving a diagnosis of  
hearing loss; and analyze the marginal effects in different groups.  
Study Sample Profile 
 The database used in this study of hearing screening and hearing loss includes a 
total of 51,244 infants either born or transferred into a single health care system in 
Central Texas between 1988 and 2009. There are statistically significant differences 
between the newborn nursery and NICU infants in all characteristics of interest, 
including the number receiving a newborn hearing screen. A larger proportion of infants 
were admitted to the newborn nursery, which might be expected since most babies are 
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born healthy and do not require a higher level of care. A larger proportion of females and 
black infants were admitted to the NICU than the newborn nursery. As might be 
expected, the NICU also had a greater proportion of infants with low birth weight and an 
early gestational age (see Table 5). Table 5 also denotes were there were missing data 
for each variable, which did impact the relative sample sizes for each separate analysis. 
Only one set of analyses, temporal trends in and likelihood of newborn hearing 
screening, include infants from the newborn nursery. All other analyses required data on 
confirmed hearing loss and, therefore, only NICU infants were included in the samples 
those portions of the study. Table 6 includes descriptive statistics for infants with an 
without confirmed hearing loss during the study period of 1996-2007. A total of 285 
infants (4.9 percent) in the sample had a diagnosis of hearing loss in their record. There 
were no differences in gender, Apgar scores, or several of the treatment factors or 
comorbidities between infants with and without hearing loss (see Table 6). The groups 
did differ in race/ethnicity, birth weight, whether or not they received a screen, 





Table 5. Characteristics of Newborn Population Admitted to Health Care System 
between 1988 and 2009 
 











Male 20,673 (49.19%) 4,158 (45.10%) Overall p<0.001 
Female 21,335 (50.77%) 5,047 (54.75%)  




White 15,077 (35.88%) 3,514 (38.12%) Overall p<0.001 
Black 4,276 (10.17%) 1,387 (15.05%)  
Hispanic 7,370 (17.54%) 1,294 (14.04%)  
Other 894 (2.13%) 119 (1.29%)  




Vaginal 34,209 (81.40%) 5,704 (61.87%) Overall p<0.001 
Cesarean 7,806 (18.57%) 3,453 (37.46%)  




>4,200g 1,810 (4.31%) 244 (2.65%) Overall p<0.001 
2,500-4,199g 39,146 (93.15%) 3,761 (40.80%)  
1,500-2,499g 1,066 (2.54%) 3,496 (37.92%)  
1,000-1,499g 2 (0.00%) 995 (10.79%)  
<1,000g 1 (0.00%) 723 (7.84%)  
Gestational Age 
>37 weeks 36,150 (86.02%) 2,948 (31.98%) Overall p<0.001 
35-37 weeks 5,297 (12.60%) 1,531 (16.61%)  
32-34 weeks 541 (1.29%) 2,313 (25.09%)  
28-31 weeks 35 (0.08%) 1,699 (18.43%)  
<28 weeks 2 (0.00%) 728 (7.90%)  
Newborn Hearing Screen 
Not screened 18,254 (56.56%) 5,883 (63.81%) Overall p<0.001 
Screened 23,768 (43.44%) 3,336 (36.19%)  
Birth Year    
Prior to 1996 14,396 (34.26%) 2,875 (31.19%) Overall p<0.001 
After 1996 27,629 (65.74%) 6,344 (68.81%)  
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Male 158 (55.44%) 3,019 (55.04%) p>0.05 
Female 127 (44.56%) 2,461 (44.87%)  




White 185 (64.91%) 3,017 (55.00%) p<0.001 
Black 33 (11.58%) 1,186 (21.62%)  
Hispanic 58 (20.35%) 1,155 (21.06%)  
Other 8 (2.81%) 101 (1.84%)  




>4,200g 10 (3.51%) 153 (2.79%) p<0.001 
2,500-4,199g 130 (45.61%) 2,441 (44.50%)  
1,500-2,499g 91 (31.93%) 2,017 (36.77%)  
1,000-1,499g 28 (9.82%) 509 (9.28%)  
<1,000g 26 (9.12%) 365 (6.65%)  
Apgar Scores    
1 minute, mean 7 7.41 p>0.05 
5 minute, mean 8.42 8.49 p>0.05 
Hearing Screening    
Not screened 10 (3.51%) 438 (7.33%) p=0.015 
Screened 275 (96.49%) 5,541 (92.67%)  
Comorbidities and Treatments 
Ventilation 74 (25.96%) 1,205 (20.15%) p=0.017 
Oxygen 100 (35.09%) 2,192 (36.66%) p>0.05 
Craniofacial 
Anomolies 7 (2.46%) 11 (0.18%) p<0.001 
Cytomegalovirus 1 (0.35%) 25 (0.42%) p>0.05 
Neonatal infection 2 (0.70%) 11 (0.18%) p>0.05 
Hyperbilirubinemia 39 (13.68%) 836 (13.98%) p>0.05 
Sepsis 19 (6.67%) 361 (6.04%) p>0.05 
Respiratory 
Distress 54 (18.95%) 1,027 (17.18%) p>0.05 
    
Length of Stay    
<=5 days 78 (27.37%) 2,097 (35.07%) p=0.008 




Newborn Hearing Screening Rates 
Since the health care system implemented newborn hearing screening in 1996, 
the annual rate of infants receiving a screen has increased to rates between 90 and 100 
percent. Prior to 2001, the rates varied by admitting unit, with infants admitted to the 
NICU having higher rates of newborn hearing screening than infants admitted to the 
newborn nursery. Since 2001, rates in both units stabilized and are above 90 percent. 
Between 1999, when the screening mandate was passed in the Texas Legislature, and 
2001, when full implementation of the law was required, there was a reduction in the 
screening rates for both admitting units, with the newborn nursery having the sharpest 
decline. Figure 4 shows the trends in screening rates since 1996. The fitted line is 
included to demonstrate the direction of the trend in overall screening rates across both 
units. As the graph shows, newborn hearing screening rates increased over the priod 




Figure 4. Newborn Hearing Screening Rates, 1996-2007 
 
 The generalized linear model showed that each year after 1996 had a statistically 
significant improvement in newborn hearing screening rates, compared to 1996 and 
adjusted for admitting unit (p-values all equal < 0.001). The NICU is also associated 
with higher screening rates (p-value<0.001).  
Loss to Follow-up Rates 
 Annual rates of loss to follow-up for infants admitted to the NICU decreased 
over the time period 1996 to 2007, demonstrating that fewer infants with positive 
newborn hearing screens were being lost due to either receiving no follow-up or not 
having documentation of follow-up services within the system. In all years except for 
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1996 the annual rate of loss to follow-up was less than 15 percent, much lower than the 
reported rate for Texas (40.2 percent in 2011). Figure 5 shows the annual rates and 
included a fitted line to demonstrate their downward trend. 
 
 
Figure 5. Loss to Follow-up Rates, NICU, 1996-2007 
 
 The generalized linear model testing for changes in the loss to follow-up rate 
showed that all years had statistically significant reductions in loss to follow-up 





Screen Specificity and False-Positive Rate 
 Specificity of a screen or test indicates the extent to which the test accurately 
identifies individuals without the disease when they truly do not have the disease. In the 
case of newborn hearing screening, this is the ability of the screen to provide negative 
results to infants that do not have hearing loss.421  The false-positive rate is the rate of 
infants that were identified through the screening program to potentially have hearing 
loss, but do not actually have hearing loss upon confirmatory testing (or, in this analysis, 
do not ever receive a hearing loss diagnosis). The higher the specificity, the lower the 
false-positive rate.421 
 The specificity of the screening program among NICU infants has maintained a 
high specificity rate, never going below 90 percent. As such, the false-positive rate as 
remained below 10 percent, with a high in 1999. Figure 6 shows the trends graphically. 
The fitted lines demonstrate that there is a general trend toward an increasingly higher 
specificity, while the false-positive rate has declined.  
 We know from conversations with physicians in the health system that they 
recognized a high false-positive rate around 1999-2000. In response, the organization 
implemented a new staff training to improve performance and interpretation of the 






Figure 6. Screen Program Specificity and False-Positive Rate, NICU, 1996-2007 
 
 The generalized linear model shows that there has been fluctuation in the 
specificity and the false-positive rate over time. Specificity was lower in 1997, 1998, 
1999, 2000, and 2001, compared to the year 1996 (p-values<0.001). In the following 
years (2002-2007), the odds of increased specificity are all greater than 1 (p-





Similarly, the false-positive rate was higher from 1997-2001, compared to 1996 
(p-values=0.000). In 2002, the odds of a lower false-positive rate become lower than one 
and remain so through 2007 (p-values<0.001).  
Screen Sensitivity and False-Negative Rates 
 The sensitivity of a screen or test is the extent to which the test accurately 
identifies individuals that have the disease of interest.421 The false-negative rate is 1-
sensitivity and represents the proportion of individuals that had a negative test or screen 
result but eventually received diagnosis of the disease.421 Tests with high sensitivity rates 
will have low false-negative rates.421  
 In general, this study of newborn hearing screening found that the sensitivity of 
the screen was low over the study period and, similarly, that the false-negative rate 
remained quite high. There was variation over the years. Figure 7 shows the changes 
over time and includes fitted lines for both sensitivity and false-negative rates to 






Figure 7. Screen Program Sensitivity and False-Negative Rate, NICU, 1996-2007 
 
 The generalized linear model shows that the odds of higher sensitivity were 
lower than one in all years except for 2001, compared to 1996 (p-values<0.001; year 
1999 had exact same sensitivity as 1996). In 2001, the odds were slightly higher than 1 
(1.04, p-value<0.001) and represent the highest annual sensitivity rate across the study 
period. The model to predict changes in false-negative rates shows that the odds of a 
higher false-negative rate were above one for all years except 2001, compared to 1996 
(p-values<0.001). These results confirm that both the screen sensitivity and false-
negative rate have not improved since the inception on newborn hearing screening 
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within the health care center in 1996 and may reflect the fact that NICU infants are at 
greater risk of delayed onset hearing loss. 
Prediction Models  
Next, I extend the focus on these program outcomes and present results of five 
separate logistic regression models to predict the likelihood of receiving a newborn 
hearing screen, being lost to follow-up, receiving a false-positive or false-negative 
screen result, and receiving a hearing loss diagnosis, all adjusted for birth year and infant 
characteristics. The results are intended to further inform hearing screening programs, 
both universal and through targeted follow-up. 
Likelihood an Infant Received a Hearing Screen 
 A total of 28,335 infants with complete data were included in our analysis of the 
likelihood an infant received a hearing screen. As noted previously, this is the one 
outcome in the study where inclusion of both the newborn nursery and neonatal 
intensive care units is possible, providing the opportunity to adjust for admitting unit. 
 Across the study sample and period, the mean probability that an infant received 
a hearing screen was 0.859. Neither gender or race was associated with increased odds 




interaction, were significantly associated with receipt of a screen, as were the 5-minute 
Apgar score, length of stay, ventilation status, and a diagnosis of hyperbilirubinemia. 
Table 7 includes the regression results for these significant covariates.  
 Compared to the year 1996, infants born between 1997 and 2007 had greatly 
increased odds of receiving a hearing screen (OR range 118 to 19,169, p-
values<0.0001). Infants admitted to the NICU were also more likely to receive a hearing 
screen (OR=118, p-value<0.0001). Higher 5-minute Apgar scores (OR=1.19, p-
value<0.0001), a length of stay greater than five days (OR=13, p-value<0.0001), and a 
diagnosis of hyperbilirubinemia during the birth admission (OR=3.19, p-value<0.0001) 
were also associated with an increased odds of receiving a hearing screening. Infants that 
were on ventilation, regardless of the length, had lower odds of receiving a hearing 
screen (OR=0.25, p-value<0.0001). The interaction between birth year and admitting 
unit was significant in the model and each individual interaction was also significant, 




Table 7. Results of Logistic Regression Analysis, Likelihood an Infant Received a 
Hearing Screen (n=28,335) 
Variable Odds Ratio P-value [95% Conf. Interval] 
     Birth Year (referent is 1996) 
1997 152.47 <0.0001 100.92 230.35 
1998 3651.24 <0.0001 2195.72 6071.61 
1999 505.90 <0.0001 331.90 771.12 
2000 118.43 <0.0001 78.48 178.72 
2001 1181.78 <0.0001 759.79 1838.13 
2002 8764.76 <0.0001 4747.52 16181.28 
2003 5997.30 <0.0001 3431.09 10482.83 
2004 10492.02 <0.0001 5487.39 20060.97 
2005 19169.58 <0.0001 8891.42 41328.92 
2006 10047.66 <0.0001 5442.53 18549.37 
2007 6044.29 <0.0001 3524.46 10365.70 
     Admitting Unit (referent is Newborn Nursery) 
NICU  188.37 <0.0001 109.41 324.32 
Apgar (5 minute) 1.19 <0.0001 1.09 1.30 
Length of stay >5 
days  13.29 <0.0001 8.86 19.94 
Ventilation  0.25 <0.0001 0.15 0.41 
Hyperbilirubinemia 
Dx 3.19 <0.0001 1.67 6.10 
     Birth Year and Unit Interaction (referent is 1996*NICU) 
1997#NICU 0.02 <0.001 0.01 0.03 
1998#NICU 0.00 <0.001 0.00 0.01 
1999#NICU 0.01 <0.001 0.00 0.01 
2000#NICU 0.02 <0.001 0.01 0.03 
2001#NICU 0.01 <0.001 0.00 0.02 
2002#NICU 0.00 <0.001 0.00 0.00 
2003#NICU 0.00 <0.001 0.00 0.00 
2004#NICU 0.00 <0.001 0.00 0.00 
2005#NICU 0.00 <0.001 0.00 0.00 
2006#NICU 0.00 <0.001 0.00 0.00 




 The estimated marginal effcts of the significant variables are summarized in 
Table 8. The overall probability of receiving a hearing screen was 0.859. The average 
marginal effects provided in the table demonstrate the relative probability of the 
different groups described and, since they are all significant variables in the model, we 
can compare probabilities between groups. For example, an infant born is 1997 was over 
four times as likely to receive a hearing screen as an infant born in 1996 (probability of 
0.698 in 1997 compared to probability of 0.157 in 1996). Similarly, infants born after 
2002 were six times as likely to receive a hearing screen. The probability of receiving a 
hearing screen in the NICU was four percent higher (0.892) than the probability of 
receiving a screen in the newborn nursery (0.84). Infant that received assisted ventilation 
had an eight percent higher probability of receiving a hearing screen, although the reason 
for this difference is not clear. The probability of hearing screening for infants with a 
length of stay greater than five days was 10 percent higher than infant admitted for five 
or fewer days, possibly due to the extended amount of time during which the screen 
could be performed. A hyperbilirubinemia diagnosis was also associated with a five 




Table 8. Average Marginal Effects for the Logistic Model of Screening Receipt 
Variable Margin P-value [95% Conf. Interval] 
Birth Year     
1996 0.157 <0.001 0.149 0.165 
1997 0.698 <0.001 0.679 0.717 
1998 0.977 <0.001 0.971 0.983 
1999 0.873 <0.001 0.860 0.887 
2000 0.647 <0.001 0.628 0.666 
2001 0.941 <0.001 0.932 0.951 
2002 0.986 <0.001 0.981 0.990 
2003 0.984 <0.001 0.979 0.988 
2004 0.985 <0.001 0.981 0.990 
2005 0.986 <0.001 0.982 0.991 
2006 0.981 <0.001 0.975 0.986 
2007 0.969 <0.001 0.960 0.978 
     
Admitting Unit     
Newborn Nursery 0.850 <0.001 0.847 0.853 
NICU 0.892 <0.001 0.876 0.909 
     
Length of Stay     
Five or less Days 0.835 <0.001 0.830 0.841 
Greater than 5 days 0.933 <0.001 0.926 0.940 
     
Ventilation Status     
No Ventilation 0.862 <0.001 0.859 0.864 
Received Ventilation 0.761 <0.001 0.718 0.804 
     
Hyperbilirubinemia Dx     
No hyperbilirubinemia 0.858 <0.001 0.856 0.861 




Likelihood an Infant is Lost to Follow-up  
 There were 5,102 eligible infants with complete data included in the analysis to 
determine the likelihood an infant is lost to follow-up. This includes only infants 
admitted to the NICU, since follow-up status could only be assessed for those infants. 
Compared to 1996, the odds an infant with a positive screen was lost to follow-up was 
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lower (ORs=0.19-0.37, p-values<0.0001) in all years except 1997, where the result was 
insignificant.  
Infants born with a birthweight between 1,000 and 1,499 grams were less likely 
to be lost to follow-up than infants greater than 4,200 grams (OR=0.45, p-value=0.027), 
but no other birthweight categories had significant differences. Black infants had greater 
odds of being lost to follow-up (OR=1.34, p-value=0.013), while Hispanic infants had 
lower odds of being lost (OR 0.64, p-value=0.002) compared to whites. 
Neither the 1-minute or 5-minute Apgar score, nor ventilation status were 
associated with an increased odds of being lost. Infants who received oxygen while in 
the NICU were more likely to be lost (OR=1.46, p-value=0.004). Infants that were 
admitted to the hospital for longer than five days had higher odds of being lost 
(OR=1.28, p-value=0.04). The only diagnosis form the birth encounter associated with 
loss to follow-up was hyperbilirubinemia, in which infants who received this diagnosis 
were less likely to be lost (OR=0.59, p-value=0.004). Table 9 includes the results of the 




Table 9. Results of Logistic Regression Analysis, Likelihood an Infant is Lost to 
Follow-up (n=5,102) 
Variable Odds Ratio P-value [95% Conf. Interval] 
Birth Year (referent is 1996) 
1997 0.72 0.098 0.49 1.06 
1998 0.28 <0.0001 0.18 0.44 
1999 0.32 <0.0001 0.19 0.52 
2000 0.19 <0.0001 0.12 0.32 
2001 0.29 <0.0001 0.18 0.45 
2002 0.30 <0.0001 0.20 0.47 
2003 0.36 <0.0001 0.23 0.56 
2004 0.26 <0.0001 0.16 0.42 
2005 0.37 <0.0001 0.24 0.56 
2006 0.33 <0.0001 0.21 0.53 
2007 0.34 <0.0001 0.19 0.60 
 
Birthweight (referent is 2,500g-4,199g) 
>4,200g 1.08 0.794 0.61 1.92 
1,500-2,499g 1.07 0.542 0.86 1.32 
1,000-1,499g 0.49 0.003 0.31 0.78 
<1,000g 0.71 0.271 0.39 1.30 
 
Race (referent is White) 
Black 1.34 0.013 1.06 1.69 
Hispanic 0.64 0.002 0.49 0.85 
Other 0.63 0.288 0.27 1.47 
     
Length of stay >5 
days  1.28 0.04 1.01 1.62 
Oxygen  1.46 0.004 1.13 1.90 
Hyperbilirubinemia 








The overall probability of being lost to follow-up was 0.0919. After assessment 
of the average marginal effects, there were no differences in probability for infants born 
in 1996 or 1997; therefore, we are unable to compare probabilities across birth years. 
However, we can compare probabilities from individual years to the overall probability. 
Infants born from 1998 to 2007 had lower probabilities of being lost to follow-up that 
the sample as a whole. The probability of being lost to follow-up for black infants was 
three percent higher than that for the overall sample, and Hispanic infants had a lower 
probability of being lost. The probability of being lost for infants that received oxygen 
during their NICU admission was three percent higher than those that did not receive 
oxygen. Infants with a length of stay longer than five days had a two percent higher 
probability of being lost to follow-up than those with a shorter length of stay. Infants 
with a hyperbilirubinemia diagnosis had a lower probability two and half percent lower 




Table 10. Average Marginal Effects for the Logistic Model of Being Lost to Follow-
up 
Variable Margin P-value [95% Conf. Interval] 
Birth Year     
1998 0.072 <0.001 0.048 0.095 
1999 0.080 <0.001 0.051 0.109 
2000 0.051 <0.001 0.030 0.071 
2001 0.073 <0.001 0.050 0.096 
2002 0.077 <0.001 0.054 0.100 
2003 0.089 <0.001 0.063 0.115 
2004 0.066 <0.001 0.043 0.089 
2005 0.091 <0.001 0.066 0.115 
2006 0.084 <0.001 0.058 0.110 
2007 0.085 <0.001 0.048 0.122 
     
Birthweight     
1,000-1,499g 0.050 0.010 0.030 0.070 
     
Race/Ethnicity     
Black 0.120 <0.001 0.101 0.140 
Hispanic 0.063 <0.001 0.049 0.078 
     
Oxygen Status     
No Oxygen 0.082 <0.001 0.072 0.092 
Received Oxygen 0.114 <0.001 0.095 0.133 
     
Length of Stay     
Five or less Days 0.079 <0.001 0.066 0.093 
Greater than 5 days 0.098 <0.001 0.088 0.108 
     
Hyperbilirubinemia Dx     
No hyperbilirubinemia 0.097 <0.001 0.088 0.105 




Likelihood of a False-Positive Hearing Screen Result 
 A total of 5,102 eligible infants with complete data were included in the analysis 
to determine the likelihood of a false-positive screen result. It was not until the year 
2002 that infants were at lower odds of receiving a false-positive screen. As mentioned 
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previously, the health care system had identified a high false-positive rate and 
implemented a staff training program to improve screening performance and 
interpretation. Likely a result of this organizational policy, infants born between 2002 
and 2007 were less likely to receive a false-positive result (ORs=0.10-0.29, p-values 
with range of <0.0001 to 0.031). Table 11 includes the complete results of the regression 
analysis. 
 Gender was not associated with false-positive results but infants with a birth 
weight less than 1,000 grams (OR=4.66, p-value=0.013) and black infants (OR=1.49, p-
value=0.048) had greater odds of a false-positive results. Those with a length of stay 
longer than five days were less likely to receive a false-positive result (OR=0.27, p-
value<0.0001), as were infants that were on oxygen during their admission (OR=0.23, p-
value<0.0001). Receipt of assisted ventilation (OR=2.60, p-value=0.008) and a diagnosis 
of persistent pulmonary hypertension (OR=44.15, p-value<0.0001) were associated with 




Table 11. Results of Logistic Regression Analysis, Likelihood of a False-Positive 
Screen Result (n=5,002) 
Variable Odds Ratio P>z [95% Conf. Interval] 
       Birth Year (referent is 1996) 
1997 0.73 0.41 0.34 1.56 
1998 0.77 0.493 0.37 1.61 
1999 1.35 0.412 0.66 2.75 
2000 0.95 0.881 0.46 1.96 
2001 0.52 0.104 0.24 1.14 
2002 0.12 <0.0001 0.04 0.35 
2003 0.29 0.01 0.11 0.74 
2004 0.12 0.001 0.03 0.41 
2005 0.10 0.001 0.03 0.37 
2006 0.26 0.007 0.10 0.69 
2007 0.18 0.031 0.04 0.85 
     Birthweight (referent is 2,500-4,199g) 
>4,200g 1.06 0.903 0.40 2.81 
1,500-2,499g 1.11 0.635 0.73 1.68 
1,000-1,499g 1.30 0.560 0.54 3.11 
<1,000g 4.97 <0.001 2.23 11.07 
     Race (referent is White) 
Black 1.49 0.048 1.00 2.20 
Hispanic 0.98 0.925 0.62 1.54 
Other 1.00 
        Length of stay >5 
days  0.27 <0.0001 0.17 0.42 
Ventilation  2.60 0.008 1.28 5.26 
Oxygen  0.23 <0.0001 0.12 0.44 
Persistent 
Pulmonary 
Hypertension Dx  








The overall probability of a false-positive screen result was 0.0302. Again, since 
not every birth year was significant in the logistic model, marginal effects are interpreted 
relative to the overall probability. From 2002 to 2007, the probability an infant received 
a false-positive screen result was lower than the overall probability. Black infants had a 
slightly higher probability than that for the overall sample. The probability of a false-
positive screen in infants born at less than 1,000 grams was three times the overall 
probability. Infants that received oxygen had a three percent lower probability of a false-
positive result than those not receiving oxygen, but infants that received assisted 
ventilation had a three percent higher probability of a false-positive result than those 
with no ventilation. Infants with a length of stay greater than five days had a four percent 
lower probability of receiving false-positive result compared to infants with a shorter 
stay. The probability of a false-positive screen for infants with a diagnosis of persistent 
pulmonary hypertension was almost 14 times the probability for infants without the 




Table 12. Average Marginal Effects for the Logistic Model of Receipt of a False-
Positive Screen Result 
Variable Margin P-value [95% Conf. Interval] 
Birth Year     
2002 0.009 0.016 0.002 0.016 
2003 0.019 0.002 0.007 0.031 
2004 0.008 0.056 0.000 0.017 
2005 0.007 0.059 0.000 0.015 
2006 0.017 0.005 0.005 0.030 
2007 0.012 0.153 -0.005 0.029 
     
Race/Ethnicity     
Black 0.039 <0.001 0.028 0.050 
     
Birth Weight     
<1,000g 0.103 <0.001 0.045 0.102 
     
Oxygen Status     
No Oxygen 0.043 <0.001 0.034 0.052 
Received 
Oxygen 0.011 <0.001 0.006 0.016 
     
Ventilation Status 
0 0.027 <0.001 0.022 0.032 
1 0.063 <0.001 0.029 0.096 
     
Length of Stay     
Five or less 
Days 0.058 <0.001 0.044 0.072 
Greater than 5 
days 0.018 <0.001 0.013 0.022 
     













Likelihood of a False-Negative Hearing Screen Result 
 There were 5,011 eligible infants included in the analysis of false-negative 
results. Unlike the results for false-positive screens, there is not a specific year in which 
a change in the odds of a false-negative screen shift and remain so. In the years 2000, 
2001, 2002, 2004, and 2007, infants had greater odds of receiving a false-negative screen 
result. Recall that NICU infants are at greater risk of hearing loss and that they are 
particularly susceptible to sensorineural hearing loss, which may have delayed onset. 
Hearing loss, in this study, was defined as the presence or absence of any hearing loss 
diagnosis, so we do not currently know if these false-negative results are due, in fact, to 
delayed onset, i.e. the infant truly did not have hearing loss at the time of their NICU 
admission.  
 Neither gender or birth weight had any association with false-negative results, 
but black infants had lower odds of receiving a false-negative screen (OR=0.32, p-
value<0.0001). A longer length of stay (OR=1.86, p-value=0.001) and diagnosis of a 
neonatal infection (OR=10.65, p-value=0.002) were positively associated with receipt of 




Table 13. Results of Logistic Regression Analysis, Receipt of a False-Negative 
Screen Result (n=5,002) 
Variable Odds Ratio P-value [95% Conf. Interval] 
     Birth Year (referent is 1996) 
1997 2.71 0.082 0.88 8.34 
1998 2.41 0.125 0.78 7.44 
1999 2.21 0.181 0.69 7.10 
2000 3.57 0.022 1.20 10.60 
2001 3.15 0.039 1.06 9.36 
2002 3.07 0.044 1.03 9.16 
2003 2.66 0.085 0.87 8.08 
2004 3.10 0.044 1.03 9.31 
2005 2.27 0.147 0.75 6.89 
2006 2.45 0.112 0.81 7.41 
2007 3.28 0.048 1.01 10.68 
     Race (referent is White) 
Black 0.32 <0.0001 0.19 0.53 
Hispanic 0.77 0.155 0.53 1.10 
Other 1.20 0.679 0.51 2.82 
 
    Length of stay >5 
days  1.86 0.001 1.28 2.72 
Oxygen  0.63 0.023 0.42 0.94 




 The overall probability of a false-negative result was 0.0392. Compared to the 
overall probability, the probability of a false-negative result was higher in the years 
2000, 2001, 2001, 2004, and 2007. Black infants had a lower probability of a false-
negative result compared to the overall sample probability. Infants on oxygen had a one 
and a half percent lower probability of a false-negative result compared to infants with 
no oxygen, while infants with a longer length of stay had two times the probability of a 
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false-negative result compared to infants with a shorter stay. Infants that had a neonatal 
infection had a probability of a false-negative result over seven times higher than those 
without a neonatal infection (see Table 14). 
 
Table 14. Average Marginal Effects for the Logistic Model of Receipt of a False-
Negative Screen Result 
Variable Margin P-value [95% Conf. Interval] 
Birth Year     
2000 0.051 <0.001 0.030 0.072 
2001 0.045 <0.001 0.027 0.064 
2002 0.044 <0.001 0.026 0.062 
2004 0.045 <0.001 0.026 0.063 
2007 0.047 0.001 0.020 0.075 
     
Race/Ethnicity     
Black 0.016 <0.001 0.009 0.023 
     
Oxygen Status     
No Oxygen 0.046 <0.001 0.037 0.055 
Received Oxygen 0.030 <0.001 0.021 0.038 
     
Length of Stay     
Five or less Days 0.026 <0.001 0.019 0.034 
Greater than 5 days 0.048 <0.001 0.039 0.056 
     
Neonatal Infection Dx     
No Neonatal Infection 0.039 <0.001 0.034 0.044 




Likelihood of a Hearing Loss Diagnosis 
 Finally, 5011 infants with complete data were included in the analysis of risk 
factors associated with an eventual hearing loss diagnosis. The model, as described 
earlier, included demographic factors and clinical characteristics that have been shown 
in the literature to be associated with hearing loss or conditions/therapies associated with 
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hearing loss. One widely known risk factor, family history, was not measurable within 
this study and, therefore, is excluded from our analysis. 
 The overall incidence of hearing loss among the study population was 5.1 
percent, which is higher than the reported incidence for the total population but not 
unlikely given the high risk of hearing loss among infant admitted to the NICU. Neither 
gender nor race were associated with a hearing loss diagnosis. Black infants had lower 
odds of hearing loss compared to white (OR=0.38, p-value<0.001), but there were no 
other differences by race/ethnicity. Among clinical indicators, Apgar scores, 
cytomegalovirus, hyperbilirubinemia, sepsis, and respiratory distress had no association 
with hearing loss.  
 Confirming the finding from other studies, length of stay greater than five days 
increased the odds of hearing loss (OR=1.68, p-value=0.002), as did assisted ventilation 
(OR=1.71, p-value=0.023). Receipt of oxygen decreased the odds of hearing loss 
(OR=0.59, p-value=0.005). Infants with a craniofacial anomaly had much greater odds 
of hearing loss (OR=12.89, p-value<0.001). Similarly, infants with a neonatal infection 




Table 15. Results of Logistic Regression Analysis, Likelihood an Infant Receives 
a Hearing Loss Diagnosis (n=4,855) 
Variable Odds Ratio P>z [95% Conf. Interval] 
Gender (referent is Female) 
Male 1.01 0.955 0.78 1.31 
Birthweight (referent is >4,200g) 
2,500-4,199g 1.07 0.856 0.51 2.23 
1,500-2,499g 0.75 0.075 0.55 1.03 
1,000-1,499g 1.07 0.790 0.65 1.78 
<1,000g 1.33 0.392 0.69 2.58 
Race (referent is White) 
Black 0.38 <0.001 0.25 0.57 
Hispanic 0.79 0.156 0.57 1.09 
Other 1.35 0.435 0.64 2.85 
Apgar (1 minute) 0.95 0.226 0.88 1.03 
Apgar (5 minute) 1.04 0.646 0.88 1.22 
Length of stay >5 
days 1.68 0.002 1.20 2.34 
Ventilation  1.71 0.023 1.08 2.72 
Oxygen 0.59 0.005 0.40 0.85 
Cytomegalovirus Dx 0.88 0.897 0.12 6.59 
Craniofacial 
Anomoly Dx  12.89 <0.001 4.44 37.38 
Neonatal Infection  7.39 0.006 1.79 30.53 
Hyperbilirubinemia 
Dx 0.98 0.919 0.68 1.41 
Sepsis Dx 0.92 0.776 0.52 1.62 
Respiratory Distress 
Dx 0.79 0.295 0.52 1.22 
The overall probability of hearing loss was 0.0506. Black infants had a two 
percent lower probability of hearing loss compared to the overall sample probability. 
Infants who received oxygen during their birth admission had a two and a half percent 
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lower probability of hearing loss compared to infants not receiving oxygen. Infants on 
ventilation had a three percent higher probability of hearing loss compared to infants 
with no ventilation. Infants with a length of stay greater than five days had a probability 
of hearing loss over two percent higher than those admitted for five or fewer days. The 
probability of hearing loss among infants with craniofacial anomalies was seven times 
the probability of those without craniofacial anomalies; and infants with a neonatal 
infection had a probability five times those without a neonatal infection (see Table 16).  
 
Table 16. Average Marginal Effects for the Logistic Model of Diagnosis of Hearing 
Loss 
Variable Margin P-value [95% Conf. Interval] 
Race/Ethnicity     
Black 0.025 <0.001 0.016 0.034 
Oxygen Status     
No Oxygen 0.061 <0.001 0.051 0.071 
Received Oxygen 0.037 <0.001 0.028 0.047 
Ventilation Status    
No Ventilation 0.046 <0.001 0.040 0.053 
Received 
Ventilation 
0.076 <0.001 0.049 0.104 
Length of Stay     
Five or less Days 0.037 <0.001 0.028 0.046 
Greater than 5 
days 0.060 <0.001 0.051 0.069 
Craniofacial Anomaly Dx       
No Craniofacial 
Anomaly 0.050 <0.001 0.044 0.056 
Craniofacial 
Anomaly 0.384 0.002 0.146 0.622 
Neonatal Infection Dx   
No Neonatal 
Infection 
0.051 <0.001 0.045 0.057 






Specific Aim 3 
 In this final section of results, I present the findings from a survival analysis 
looking at the time-to-diagnosis of hearing loss. As summarized previously, earlier 
diagnosis of hearing loss can lead to better communication skills and school 
performance.7, 45  The outcome of interest is the length of time between discharge and 
diagnosis of hearing loss, measured in 30 day periods for easy translation into years. Of 
note, the hazard of interest here is diagnosis and, contrary to many survival studies 
where death or disease may be the hazard, the presence of a hearing loss diagnosis is 
positive if we presume that earlier diagnosis leads to earlier intervention. A hazard ratio 
greater than one indicates a higher likelihood of diagnosis, compared to the reference 
group, during the time period of the study. Important here, and what is different from the 
prior analyses of hearing loss using logistic regression, is that these models are adjusted 
for screening status (negative result, positive result, no screen) in an effort to understand 
timing of diagnosis related to the screening program. Of note, follow-up records are 
available through the year 2013, so we have a minimum of six years of potential follow-
up data and a maximum of 17 years for infants born 1996 to 2007. 
First, I present the mean time-to-diagnosis for each birth year included in the 
study. Then, the Kaplan-Meier survival curves for hearing screen result are reviewed to 
demonstrate the differences in time-to-diagnosis for the different groups. Finally, I 
present results of a stratified Cox proportional hazards regression model, and then the 
Kaplan-Meier survival curves for factors associated with earlier diagnosis. Hazard ratios 
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are not available for hearing screen status as this variable violated the proportional 
hazards assumption and therefore, the model was stratified by screen status. 
Time-to-Diagnosis by Year 
The median time-to-diagnosis decreased from 1996 to 2007. In 1996 the median 
time-to-diagnosis was approximately 5.9 years (range: 1.3-11.1) and decreased to 3.3 
years by 2007 (range: 0.8-5.5) (see Table 17 for annual means and ranges). An 
independent t-test for the difference in mean time-to-diagnosis before and after full 
implementation of the newborn screening mandate in Texas (2001) indicates that the 
means are significantly different and that the difference is greater than 0 (p-
value=0.004). Figure 8 visually depicts this downward trend in time-to-diagnosis. While 
providing evidence of adownward trend, these results do not take into account the fact 
that infants born in different years have different lengths of follow-up. 
Table 17. Median Time to Hearing Loss Diagnosis, in Years 
Birth Year Median Time-to-Diagnosis, in years Minimum Maximum 
1996 5.9 1.3 11.1 
1997 5.5 0.1 16.1 
1998 4.3 0.7 14.8 
1999 5.3 0.2 13.0 
2000 4.9 0.3 11.1 
2001 4.1 0.1 10.9 
2002 4.3 0.1 10.9 
2003 5.7 0.3 10.0 
2004 3.9 0.8 9.0 
2005 4.3 0.3 6.4 
2006 4.9 0.1 7.1 
2007 3.3 0.8 5.5 
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Figure 8. Median Time-to-Diagnosis, NICU Graduates 
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Survival Estimates by Hearing Screen Status 
The Kaplan-Meier survival curve for hearing screen result (shown in Figure 9) 
shows that the probability of a hearing loss diagnosis early in the study period was 
greater among infants that failed the newborn hearing screen, suggesting that the 
screening program is leading to earlier diagnosis in infants who do have hearing loss. A 
log-rank test for equality of survival curves confirms that these curves are significantly 
different (chi2=181.51, p-value<0.0001). The findings under Specific Aim 2 suggested 
that the false-negative rate among NICU infants is somewhat high, possibly due to 
delayed onset of hearing loss or other unmeasured factors. In Figure 9, we can see that 
the survival curve for infants who had a negative screen result are very close to the curve 
for infants that did not receive a screen at all.  
While the Kaplan-Meier survival curve demonstrates that infants identified 
through screening receive earlier diagnosis, it is also influenced by the low incidence of 
hearing loss and sensitivity of the screening test (sensitivity = 0.2 in the overall sample 
and highly variable by year). So we do not see a steeper downward slope of the survival 
curve for infants who failed the screen as we would expect with a higher sensitivity. In 
this cohort, the sensitivity is low possibly due to delayed onset hearing loss and the 
inability to determine if diagnosis occurred outside of the health system.  
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Figure 9. Kaplan-Meier Survival Estimates, by Hearing Screen Status 
Cox Proportional Hazards Regression 
A total of 4,855 eligible NICU infants with complete information, including 255 
with a confirmed diagnosis of hearing loss, were included in the survival study. Infants 
born in the year 2000, and each subsequent year through 2007, were more likely to 
receive a hearing loss diagnosis during the monitored time period, compared to infants 
born in 1996. For example, the hazard ratio for the year 2007 is 4.55 (p-value=0.001)  
85 
indicating that infants with hearing loss that were born in 2007 were 4.55 times as likely 
as those born in 1996 to receive a hearing loss diagnosis during the period in which they 
received services in the health care system. As a reminder, these results are adjusted for 
hearing screen result using stratification. The complete results are available in Table 18. 
The remaining significant predictors of hearing loss diagnosis confirm the prior 
results presented in the logistic model predicting hearing loss, with one exception. 
Infants with a length of stay greater than five days, those having received assisted 
ventilation during their admission, those with a craniofacial anomaly, and infants with 
neonatal infections were more likely to receive a hearing loss diagnosis during the study 
period, while black infants were less likely to receive a diagnosis (see Table 18). 
However, this analysis finds that infants in the racial category of  “other” were more 
likely to receive diagnosis when adjusted for screening status (hazard ratio = 2.26, p-
value=0.026).  
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Table 18. Cox Proportional Hazards Model Results, Hearing Loss Diagnosis 
(n=4,855) 
Variable Hazard Ratio P>z [95% Conf. Interval] 
1997 2.07 0.085 0.90 4.74 
1998 2.06 0.09 0.89 4.76 
1999 1.73 0.229 0.71 4.24 
2000 2.76 0.014 1.23 6.19 
2001 3.02 0.007 1.35 6.76 
2002 3.61 0.002 1.60 8.13 
2003 2.49 0.033 1.07 5.77 
2004 3.39 0.004 1.46 7.86 
2005 3.20 0.008 1.36 7.55 
2006 3.49 0.004 1.50 8.11 
2007 4.55 0.001 1.81 11.48 
Gender (referent is Female) 
Male 1.00 0.981 0.78 1.29 
Birthweight (referent is 2,500-4,199g ) 
>4,200g 1.06 0.862 0.52 2.19 
1,500-2,499g 0.79 0.117 0.58 1.06 
1,000-1,499g 1.16 0.534 0.72 1.86 
<1,000g 1.40 0.283 0.76 2.59 
Race (referent is White) 
Black 0.41 <0.001 0.28 0.62 
Hispanic 0.77 0.111 0.56 1.06 
Other 2.26 0.026 1.10 4.64 
Length of stay >5 days 1.93 <0.001 1.40 2.66 
Ventilation  1.60 0.041 1.02 2.52 
Craniofacial Anomoly 
Dx  4.58 <0.001 1.96 10.69 
Neonatal Infection  5.24 0.023 1.25 21.86 
Survival Estimates for Significant Model Covariates 
The Kaplan-Meier Survival Curves presented below are for each of the 
significant variable from the Cox Proportional hazards regression model. Figure 10 
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shows that the probability of diagnosis early in the study period for infants categorized 
as having a racial category of other was higher than for the other groups (log rank test 
for equality: chi2=19.13, p-value=0.0003).  
Figure 10. Kaplan-Meier Survival Estimates, by Race/Ethnicity 
Figure 11 demonstrates that infants with a longer length of stay in the NICU also 
have a higher probability of early diagnosis than those with a stay five or fewer days (log 
rank test for equality: chi2=13.29, p-value=0.0003). Infants with longer lengths of stay 
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are likely sicker and require more frequent follow-up after discharge from the NICU, 
which may be the reason early diagnosis of hearing loss is more likely in this group. 
Figure 11. Kaplan-Meier Survival Estimates, by Length of Stay 
Figure 12 shows that infants with diagnoses of craniofacial anomalies (log rank 
test for equality: chi2=63.53, p-value<0.0001) are more likely to receive earlier 
diagnosis of hearing loss. This diagnosis increases the likelihood of both hearing loss 
and of early diagnosis of hearing loss. Although neonatal infections increase the odds of 
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hearing loss (see Specific Aim 2), there is no difference in the survival functions for 
those infants with and without infections.  
 
 




DISCUSSION AND CONCLUSIONS 
 
Given the differing scope of methodologies used in Specific Aim 1 versus 
Specific Aims 2 and 3, the discussion below is separated into sections focusing first on 
the outcomes of the systematic review of neonatal databases and then on the findings 
from the portion of the study evaluating outcomes of newborn hearing screening.  
Specific Aim 1 
Although birth outcomes such as prematurity and LBW may be relatively rare, 
infants with these outcomes and related conditions are more likely now than ever to 
survive their birth admission and receive community-based care in infancy and 
childhood. Often this care requires treatment of morbidities or chronic conditions 
associated with birth status or treatment thereafter, which motivates researchers to study 
short- and long-term outcomes that inform the practice of neonatology and pediatrics.  
Three large databases focusing on premature, LBW, and/or very acutely ill 
neonates are available to researchers seeking to understand and improve birth and long-
term outcomes for those infants. To date, an increasing number of studies using the three 
neonatal research databases have been published in the literature, and these studies use 
both prospective and retrospective research designs.  
The studies include research in clinical areas important to advancing neonatal 
and pediatric medicine. For example, ten studies included in this review are part of the 
body of research on antenatal steroid use in mothers at risk of preterm delivery, and have 
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contributed to the body of research demonstrating both the risks and benefits of antenatal 
steroid use. Further, over 20 studies focus on encephalopathy, a condition affecting 
moderately premature infants. This is an important enough issue in neonatal medicine 
that an entirely separate registry was developed by the Vermont Oxford Network to 
allow for quality improvement and research efforts specific to encephalopathy. The 
diversity of studies published using one of the three databases is extensive and 
demonstrates the versatility that such databases provide to clinical and health services 
researchers. 
The databases included in the review under Specific Aim 1 offer several 
advantages for researchers. First, each of the databases includes a large number of 
infants allowing for larger sample sizes and improved statistical power, especially when 
studying rarer conditions such as heart defects. Second, the databases include infants 
born or treated at multiple centers from diverse geographies, improving the likelihood of 
obtaining generalizable results in epidemiologic studies. Finally, the databases each have 
significant administrative guidelines and support, which provides researchers with valid 
and reliable data. 
While a large proportion of studies focus on outcomes, there are variations in 
how long these outcomes are monitored within each database. The length of follow-up 
within each database varies, with many studies following infants through discharge from 
the NICU or hospital, and others, especially those with prospective data collection, 
follow infants into childhood. Nevertheless, consistent durations of long-term follow-up 
is currently limited. Researchers seeking to study disease epidemiology and long-term 
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outcomes may find opportunities with single center databases with smaller sample sizes. 
Single-center retrospective databases may offer data that are easier to obtain 
administratively and may be available for many years on each infant.   
Study Limitations 
This review of studies utilizing data from existing neonatal databases expands on 
the work of Wright and Papile74 and provides new information about how research on 
premature and LBW infants is evolving. The review is limited by a very focused search 
strategy that used the database names and abbreviations as the only search terms, which 
may have caused me to miss some studies that used the databases but did not reference 
the data source in the same way I searched. Even so, the search yielded 343 studies that 
were ultimately included in the review and I believe that this provides adequate power to 
show trends in this research area. 
Implications for Research Practice 
Research into treatment and outcomes of premature and LBW infants is 
expanding, partially due to the availability of large, multicenter databases. The 
consistency of clinical conditions and neonatal outcomes studied since 1990 
demonstrates that there are dedicated research agendas and resources that allow for long-
term, and potentially replicable, studies within this population. Alternatively, the 
diversity of research topics and outcomes establishes an environment in which 
researchers can study new and innovative interventions or even some of the more rare 
conditions for which premature and LBW infants are at risk. These trends in neonatal 
research, specifically research focused on premature and LBW infants, offer a strong 
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foundation for future research efforts to inform neonatology, pediatric and perhaps even 
adult medicine with the remarkable improvements in survivability and improved long-
term outcomes for these medically fragile infants. 
 The choice of a single center database for this study of newborn hearing 
screening was intentional and based on the fact that the database had data on hearing 
screening results and an average of ten years of follow-up on infants admitted to the 
NICU. Additionally, the database allowed for examination of epidemiologic trends in the 
outcomes important to newborn hearing screening since the data were systematically 
collected over the course of many years. The comprehensiveness of the available data 
and the extent of follow-up available (78 percent with confirmed follow-up, mean of 10 
years) provided me with confidence in the internal validity of and ability to make 
inferences within the study. 
Specific Aims 2 and 3 
 Implementation of newborn hearing screening within this single integrated health 
care system has improved since 1996, the first year of screening. Since then the 
proportion of infants receiving a screen has improved to steady rates around 98 percent 
in the final years of study. Screening rates were already improving prior to the 1999 
passage of HB 714 in Texas, which required screening for all but the smallest hospitals 
and mandated full implementation by 2001. Between 1999 and 2001, the health system 
saw a slight decrease in screening rates and the cause of this is unclear, although it could 
be due to reassessment of organizational protocol to meet the requirements of the new 
law. After 2001, screening rates continued to steadily increase and stabilize. Screening 
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clearly targeted infants admitted to the NICU, presumably due to their increased risk, in 
the early years of the program, although screening rates in the newborn nursery were 
virtually equivalent to those in the NICU by 2001. 
 The health system also experienced a decrease in loss to follow-up over the study 
period. The system maintains a high rate of follow-up among infants admitted to the 
NICU, and this results of this study demonstrate that a high proportion of those infants 
are likely to have the opportunity for a hearing loss diagnosis within the system if they 
do, in fact, have hearing loss. Despite low overall rates of loss to follow-up, black infants 
are more likely to be lost to follow-up compared to white infants, suggesting that 
discharge planning for high-risk black infants may be useful in ensuring follow-up 
services after a positive hearing screen. 
 Over time, the specificity of the screen has improved, leading to a decrease in the 
relative number of false-positive results. Even with the general decline in false-positives, 
the rate had a period of increase in the late 1990s. Clinicians from the health system have 
advised that this increase was recognized and an organizational policy around staff 
training for quality improvement was implemented around 2000 or 2001. The data show 
that, after 2001, the false-positive rate improved to what is expected in a universal 
newborn hearing screening program, suggesting that organizational quality improvement 
initiatives can impact screening outcomes. After adjusting for birth year and other 
covariates, infants with extremely LBW, black infants, those that received assisted 
ventilation, and infants that received a diagnosis of persistent pulmonary hypertension 
were more likely to receive a false-positive screen result. This supports other study 
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findings that rescreening prior to discharge may reduce the rate of false-positives422 and 
may further suggest that targeted rescreening is useful. 
 The sensitivity of the hearing screen, and associated false-negative rate, had less 
improvement over time and demonstrated less consistency across any given year. There 
is no single year where we observe a sustainable positive shift in the false-negative rate 
so this issue remains a prominent challenge, at least as of 2007. Infants with a longer 
length of stay and those with neonatal infections had an increased likelihood of a false-
negative result, which indicates that targeted follow-up among these infants is important 
to ensure the earliest diagnosis possible. This assessment of false-negative rates may be 
biased due to the way in which I coded for hearing loss. All types of hearing loss are 
included and there is no differentiation between conductive, sensorineural, or delayed 
onset. The findings related to the high false-negative rate may be unusually high given 
the increased risk of delayed onset among NICU infants.23 Further, it is not possible 
through the database to determine if there were post-discharge factors, such as head 
trauma, that led to hearing loss. In either case, the infants would not have had hearing 
loss during their birth admission and, therefore, a negative screen result at that time was 
probably accurate. As such, these results should be interpreted with some caution until 
future research determines the types of hearing loss actually diagnosed. 
 In this study, infants with a higher likelihood of hearing loss include those with 
craniofacial anomalies, neonatal infection, a length of stay greater than five days, and 
those receiving ventilation, confirming several risk factors cited by the JCIH, USPSTF, 
and other studies.1, 10, 15-19 However, there was no difference in likelihood for infants 
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with hyperbilirubinemia or for those with LBW. Black infants had a lower probability of 
hearing loss in contrast to findings of other studies,22 but they were also at higher risk of 
being lost to follow-up so diagnostic information may be missing. Receipt of oxygen is 
paradoxically associated with less likelihood of hearing loss, but there is no evidence 
from the literature that oxygen treatment is protective and there may be unmeasured 
clinical factors associated with these decreased odds. When adjusting for screening 
status in the Cox proportional hazards model, these results are mostly confirmed. 
However oxygen status no longer has an association with hearing loss while infants 
categorized as having “other race/ethnicity” have an increased likelihood of being 
diagnosed with hearing loss. Again, this may be due to unmeasured confounders since 
screening status is unlikely to have a causal relationship with hearing status.  
 Over the study period, the mean time-to-diagnosis has decreased and the 
difference prior to and after full implementation of HB 714 is statistically significant, 
although it was already declining. Infants that receive a positive hearing screen have a 
higher probability of early diagnosis, suggesting that the underlying motivations for 
universal newborn hearing screening are justified. Black infants have a slightly higher 
probability of later diagnosis, while infants categorized as “other race/ethnicity” have the 
highest probability of early diagnosis. Time-to-diagnosis for infants with certain risk 
factors for hearing loss (craniofacial anomalies, longer length of stay) are more likely to 
receive early diagnosis. Infants with a false-negative screen result had a probability of 
early diagnosis close to that for infants that had no screening at all. This may indicate 
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that targeted follow-up of high risk infants that did not fail the newborn hearing screen is 
a means to improving time-to-diagnosis. 
Study Limitations 
 This study includes several limitations. First, I was unable to include family 
history in the models due to unavailable data. This means the models are missing a well-
documented risk factor for hearing loss, and a potential predictor of other outcomes such 
as loss to follow-up (presuming that families with a history of hearing loss are more 
aware of the need for early diagnosis and, therefore, are more likely to follow through 
with diagnostic assessment). Second, the study does not discern between types of 
hearing loss, which may impact interpretation of false-negative screen results. Infants 
documented in the study may actually have delayed onset hearing loss or other causes 
not related to the birth encounter, meaning that they were not likely to be identified 
through screening in the first place. Third, the data used in analysis are from the time 
period 1996 to 2007 and there could have been significant changes in program 
implementation and outcomes since that time. The 2007 JCIH statement includes a 
recommendation for routine follow-up and monitoring of high-risk infants, which may 
lead to earlier diagnosis among infants not identified through newborn screening after 
2007, but was not measurable in the study.  
Finally, this study focuses on implementation of screening within a single health 
system, potentially limiting the external validity or generalizability of the results to other 
centers or populations. Further, the health system began screening earlier than was 
mandated by law suggesting high levels of clinical and organizational motivation for 
 98 
 
change possibly not true of all systems; and the center maintains a rate of follow-up that 
may not exist in other systems. This may limit the application of our results to other 
organizational or clinical settings. Even with these limitations, there are policy and 
clinical implications that arise.  
Policy Implications 
 The findings from this study provide further evidence in support of universal 
newborn hearing screening, namely the findings that hospital-based implementation is 
successful and that screening leads to earlier diagnosis for infants with hearing loss. 
Nevertheless, identification of hearing loss among high risk infants admitted to the 
NICU remains challenging. The high rate of false-negative screen results suggests that 
the JCIH recommendation for targeted follow-up and monitoring of high risk infants is 
justified. Coordination of efforts to ensure follow-up of these infants should be 
undertaken at both the state and organizational level.  
Statewide rates of loss to follow up are high (approximately 40% in Texas in 
2011), making the study of screening program outcomes difficult. However, studies 
within integrated health systems providing continuous care to infants after hospital 
discharge may provide insights into program success and opportunities for improvement. 
As state newborn screening programs expand to include other point-of-care 
screening programs such as that for critical congenital heart disease, there is much to be 
learned from the history of newborn hearing screening. Facilitating quality improvement 
efforts, such as staff training programs, at local hospitals may be a particularly important 
component of any state law requiring universal screening at the bedside. Contrary to 
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traditional blood spot screening where state employees analyze, interpret, and follow-up 
on the screen, point-of-care screening shifts the burden of interpretation, parental 
notification, and referral to hospital staff.  
Clinical Implications 
 Clinicians and health systems can use the results of this study, and others, to 
identify opportunities to improve screening and follow-up. For example, infants with 
persistent pulmonary hypertension had a high probability of false-positive results so 
NICUs can consider rescreening prior to discharge to avoid time consuming and costly 
diagnostic testing. Similarly, targeted follow-up of infants with a length of stay longer 
than five days and those with neonatal infections may lead to earlier identification of 
hearing loss and earlier intervention. NICU follow-up clinics should continue to 
emphasize developmental screening, including that focused on assessing potential 
hearing loss.  
 Physicians can use the results of this study to identify infants at risk for any of 
the outcomes studied. Discharge planning should take into account the risk for false-
positive and false-negative results into account. For example, the study finds that the 
probability of false-negative results were seven times higher for infants with neonatal 
infections compared to those without. This information may alert providers to the need 
for referral for follow-up despite the screening result, and in addition to the usual referral 
for general follow-up after NICU discharge. Similarly, community-based pediatricians 
caring for these infants after discharge and throughout childhood should be aware of 
infant and clinical risk factors that increase the risk of hearing loss, especially among 
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populations of infants with a high probability of false-negative screen results. The 
average marginal effects associated with the logistic models presented in this study may 
be particularly useful in clinical education and training, as they are easily interpretable 
and applicable to individual patients. 
Future Research 
This study of hospital-based implementation of newborn hearing screening 
provides evidence for continuing universal newborn hearing screening, and makes 
recommendations for policy and practice. There are several opportunities for future 
research. First, this study should be expanded to include an analysis of the different 
types of hearing loss, specifically sensorineural hearing loss. NICU infants are at high 
risk of sensorineural hearing loss, which may have delayed onset. Analyses focused on 
the type of hearing loss may provide further explanation of the findings related to false-
negative screen results and delayed time-to-diagnosis for infants with a false-negative.  
 Second, current procedural terminology (CPT) codes could be used to assess 
whether infants were receiving the intervention services as recommended by the JCIH. 
CPT codes would allow researchers to document services such as hearing and 
developmental assessments and receipt of amplification devices, potentially 
strengthening the general knowledge about factors associated with specific follow-up 
services, not just diagnosis.  
Third, the study should be extended to the period after 2007 to identify progress 
in implementing Texas HB411, which provided follow-up guidelines and reporting 
requirements for hospitals and community-based practitioners. Finally, cost-
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effectiveness studies could utilize the findings from this study, especially the marginal 
effects identified, to determine the marginal costs associated with outcomes such as 
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